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Abstract

Retinal diseases are personally debilitating and expensive, yet many early disease
mechanisms leading to their onset and progression remain poorly understood. The
harlequin mouse is a model of human mitochondrial dysfunction and parainflammation
leading to subsequent cerebellar and retinal degeneration. Diagnosis of retinal
degeneration can be tracked in vivo and is associated with AIF dysfunction. Here, retinal
dysfunction in the harlequin mouse was first quantified using electroretinography
followed by assay of blood-retinal-barrier integrity and transcriptome alterations in young
adulthood. Nonmetric multidimensional scaling of oscillatory potentials provided a
novel, comprehensive assessment of inner-retinal health and can detect shifts in OP
parameters. Barrier integrity ruled out confounding exogenous antigens and confirmed an
endogenous source of retinal tissue malfunction. In addition, transcriptome alterations
support the necessity of the hq retina to maintain metabolic demands. Alternative
metabolism pathways are hypothesized to be important for hq complex I mitochondrialdysfunction associated retinal degeneration.

Keywords: harlequin, Apoptosis-inducing factor, retinal degeneration, mitochondrial
dysfunction, electroretinography, oscillatory potentials, nonmetric multidimensional
scaling, blood retina barrier, Evans Blue, ATP deficiency, quantitative gene expression,
glycerol metabolism.
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Chapter 1. Introduction
1.1 Increased prevalence of neurodegenerative disorders in an increasingly aged
population
Neurodegenerative diseases are characterized by progressive functional deficiencies
and cell death of neurons resulting in nervous system dysfunction. Medical advances in
cardiovascular diseases, cancers and other common illnesses have increased human
longevity

and

thereby

increased

prevalence

of

neurodegenerative

disorders.1

Predispositions from familial and environmental risk factors may also play a role in
neurodegenerative disease onset and progression, however, the highest propensity of
disease risk occurs with age.2 Despite high prevalence and extreme negative
consequences to quality of life, the causes and early disease mechanisms of such diseases
remain unknown.
In Canada, it is expected that within 25 years the number of seniors will double to
well over 9.9 million people and surpass the age demographic of 0-14 year olds for the
first time in Canadian history (Population Projections for Canada, Provinces and
Territories. 2009-2036).3 Common retinal degenerative diseases such as: age-related
macular degeneration (AMD), diabetic retinopathy (DR) and open-angle glaucoma
(OAG) affect well over 1.75 million Canadians and the prevalence of such diseases is
expected to rise proportionally (CNIB Report, 2009).4 These three diseases fall under the
umbrella term of “vision loss” and have the highest direct healthcare costs of any disease
in Canada at $8.6 billion annually.4 Despite this high level of expenditure, little is known
about early disease mechanisms and prevention leaving the diseases personally
debilitating and expensive. Vision research remains critical for increasing the quality of

2
life of affected individuals and also for reducing expenditures as the increasingly aged
population brings alarming financial demands.

1.2 Mechanisms of common retinal degenerative diseases remain unclear
As the Canadian population shifts towards an older demographic cohort, the
prevalence of common retinal degenerative disorders is expected to rise.4 These common
diseases are progressive and require continual and enhanced treatment as the disease
advances. Retinal degenerative disorders can lead to losses of central, peripheral, and
even complete vision in the later stages of disease progression. Unfortunately, disease
mechanisms and triggers leading to neuronal death are numerous and little is known
about initiating mechanisms that cause retinal degeneration.
Age-related macular degeneration (AMD) is a prevalent retinal degenerative
disorder affecting over one million Canadians and is the leading cause of irreversible
blindness in the developed world.4,5 AMD begins with the deposition of acellular protein
and lipid debris, known as drusen, in the space behind the retina around the macula.6 The
macula contains the highest density of cone photoreceptors in the primate eye and is
responsible for the central vision acuity that we appreciate as human beings.7 Excess
drusen can cause damage to the retina and lead to hypoxia. Hypoxia induces the
expression of angiogenic cytokines, such as vascular endothelial growth factor (VEGF),
causing neovascularization in the macula and leading to subsequent central vision loss.5
Diabetic retinopathy (DR) is the second-most prevalent retinal degenerative
disorder affecting over 500,000 Canadians.4 It is a common complication of diabetes
caused by hyperglycemia, hypoxia and neovascularization.8 The exact mechanisms by
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which DR causes neovascularization and progressive retinal degeneration remain poorly
understood.
Open-angle glaucoma (OAG) is the third-most prevalent retinal degenerative
disorder affecting over 250,000 Canadians.4 Glaucoma is often caused by an increase in
intraocular pressure leading to optic neuropathy.4 Increases in intraocular pressure caused
by reduced aqueous humor drainage lead to progressive retinal neuron axon loss,
particularly along the optic nerve.9 Mechanisms that drive retinal cell loss remain
unknown and lead to peripheral vision loss with no preventative treatment available.10
The progressive symptoms associated with these common retinal degenerative
diseases are clearly characterized and various treatments are available in the later
advancements of the disease. However, early mechanisms and triggers leading to retinal
degenerative disorders are poorly understood and treatment is only available after cell
damage has already begun. Therefore, to increase the quality of life, an understanding of
early disease mechanisms is critical to limit disease onset and progression.

1.3 The physiology and anatomy of a healthy retina is complex
The retina is one of the most complex structures of the vertebrate eye and a key
component of the visual pathway (Figure 1.1A). The retina is a light-sensitive tissue that
lies in the posterior region of the vertebrate eye and is divided into two regions known as
the neural retinal and retinal pigmented epithelium (RPE) (Figure 1.1B).7 These two
anatomical regions develop from the embryonic forebrain and undergo complex
differentiation and ultimately function as an outcropping of the central nervous system.11

4
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Figure 1.1 A cross-section of the mouse eye and retina stained with Hemotoxylin and
Eosin. (A) A C-cut section of the mouse eye demonstrates similar anatomical features of
the human eye including the cornea, lens, pupil, iris, retina, scalera and optic nerve.
Representative wild-type mouse eye adapted from MacPherson (2009).19 (B,C) A crosssection of the mouse retina indicates the distinct retinal cells layers. Light must transverse
all layers of the retina prior to excitation of the photoreceptors which are positioned in the
outer segment (OS). The retinal pigment epithelium (RPE) lies at the base of the retina
and absorbs any stray photons of light not absorbed by photoreceptors. In addition, the
RPE separates the retina from the posterior choroid and acts as a nutrient shuttle.
Phototransduction begins in the OS as the electrochemical signal is conveyed through the
outer nuclear layer (ONL) and synapses through the outer plexiform layer (OPL) onto the
horizontal cells and bipolar cells of the inner nuclear layer (INL). The electrochemical
signal is then relayed to the amacrine and ganglion cells of the ganglion cell layer (GCL)
through the inner plexiform layer (IPL). The electrochemical signal leaves the GCL via
the optic nerve where it is transmitted to the visual cortex for interpretation.
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The design of the mammalian retina is counter-intuitive in nature because light
must cross all neural retinal layers prior to the excitation of photoreceptors. Thereby,
photoreceptors are positioned at the most posterior region of the neural retina, only
posteriorly superseded by the RPE (Figure 1.1B).12 This is due to the fact that the RPE
continuously supplies nutrients to the highly metabolic photoreceptors.11 The RPE is a
monolayer of pigmented cells that separates the internal choroid from the neural retina
and acts as a nutrient shuttle, providing a steady stream of 11-cis retinal, glucose, and
fatty acids from the choroid to the outer segment of the photoreceptors.13–15 The RPE also
plays an essential role in the recycling of all-trans retinal back into 11-cis retinal once it
has been isomerized by light.14,13 The RPE is highly pigmented, containing a high
proportion of melanin granules that absorb stray photons of light in the retina to enhance
vision acuity and reduce exposure to light radiation.7 In addition, the RPE creates an
outer blood-retinal-barrier (BRB) through epithelium tight junctions which maintains
optimal homeostatic conditions for retinal neurons.15
Anterior to the RPE lies the neural retina composed of six differentiated layers
(posterior to anterior) (Figure 1.1B,C). The outer segment (OS) contains the familiar rod
and cone photoreceptors responsible for the initial absorption of light and relay of
electrochemical signal.7 All vertebrate retinas contain both rod and cone photoreceptors
which differ by their absorption wavelength and cell morphology. Rods are thin, rodshaped structures that are highly sensitive to blue-green light (500 nm) and are densely
packed with the visual surface photopigment rhodopsin. Rods are generally used for lowlight vision (scotopic vision) and make up 95-97% of all photoreceptors in the
mammalian eye (human 95%).7,16 Cones are large, conical structures that are densely
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packed with opsin photopigments and are sensitive to daylight and bright colours
(photopic vision). Three types of cones with different associated opsin photopigments
exist in the human retina, each responsible for the absorption of a different wavelength of
light: red (559 nm), green (431 nm) or blue (419 nm).16 This provides the trichromatic
vision that we appreciate as humans. The inner segment (IS) contains the cell bodies of
the photoreceptors and is responsible for maintaining metabolism.16 In the outer nuclear
layer (ONL) lie the nuclei of the photoreceptors. The outer plexiform layer (OPL) is a
thin region of synaptic connections between the photoreceptors and the neural cells of the
inner nuclear layer (INL). The outer plexiform layer (OPL) is a region densely populated
with axons from the rod and cone photoreceptors and neurites of bipolar and horizontal
cells.11 Eleven types of human bipolar cells exist in the INL, the most common being
bipolar cells connecting photoreceptors with ganglion cells through the release of
glutamate.11 Horizontal cells have a large lateral extension across the retina and synapse
back onto rod and cone photoreceptors in an inhibitory manner.17 This provides a level of
local gain in the retina and allows image processing to begin through inhibiting lightsaturated photoreceptors to prevent scattering of light in the retina.18 The INL also
contains the nuclei of amacrine cells which mediate the effect of the ON-,OFF- bipolar
cells on ganglion cells through the release of neurotransmitters, glycine and gammaaminobutyric acid (GABA).18 These mechanisms assist with the early building of images
in the retina.7 Synapsis of bipolar and amacrine with ganglion neurons occurs in the inner
plexiform layer (IPL). The innermost layer of the retina is the ganglion cell layer (GCL)
which contains both the axons and nuclei of the ganglion cells and is responsible for
relaying electrochemical signals to the visual cortex via the optic nerve.

8
1.4 Phototransduction is compromised in retinal degeneration
Phototransduction is the process in which photons of light excite photopigments in
the photoreceptor cells to generate an electrical response.20 First, light must travel
through all layers of the retina and will only activate photoreceptors in the field of
reference.

In rod photoreceptors, rhodopsin is the primary photopigment and is

covalently linked to the chromophore, 11-cis retinal.21 During the absorption of light, 11cis retinal is converted to all-trans retinal through photoisomerization.20 Conformational
changes of rhodopsin are capable of activating photoreceptor-specific G-protein,
transducin.20 Transducin stimulates the activity of cGMP phosphodiesterase, resulting in
a reduction of cytoplasmic cGMP concentration and subsequent closure of cGMP gated
channels.22 Closure of the cGMP channels results in a decrease of Na+ and Ca2+ influx
triggering membrane hyperpolarization and reduced release of synaptic neurotransmitter,
glutamate.20 Glutamate is the principal neurotransmitter involved in electrochemical
transmission in the retina.7 Unlike common nerve cell function, photoreceptors release
glutamate in the dark as Na+ and Ca2+ flow freely across the phospholipid membrane.20
Upon light stimulus, glutamate release is hindered in photoreceptors and leads to
subsequent depolarization of bipolar, horizontal and amacrine cells of the INL.22 This
signal is further processed by the GCL before travelling to the visual cortex via the optic
nerve. Phototransduction occurs in a similar fashion in cone photoreceptors, however,
opsin proteins vary slightly in their optimal absorption wavelength. Phototransduction is
imperative to normal retinal function and vision. Common retinal degenerative diseases
can lead to damage of the photoreceptors and phototransduction pathway by various
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disease factors including: age, light toxicity, diabetes, hypertension, genetic mutations,
vitamin A deficiency, angiogenesis, parainflammation and mitochondrial dysfunction.23,24

1.5 Neuronal homeostasis is maintained by glial cells of the retina
Three types of resident glial cells reside in the retina and are essential for retinal
function and homeostasis, these include Müller cells, astroglia, and microglia cells.
Müller cells are the most abundant glia of the retina and provide architectural support
across all neural layers.25 Müller cell bodies sit in the INL and perform a variety of
functions including: the breakdown of glycogen for anaerobic metabolism,26 removal of
excess neurotransmitters from the subretinal space,27 assistance with phagocytosis of
apoptotic neurons and neuronal debris,28 assistance with the formation of the BRB29 as
well as maintaining ionic homeostasis in the retina by recycling K+.30 Astroglia are the
supportive glia that originate in the optic nerve head and are subsequently present in the
GCL.31,32 Similar to Müller cells, they assist with the formation of barrier properties by
vascular endothelial cells,29,33,34

the breakdown of glycogen for neuron nutritive

support,26 and regulation of ionic homeostasis30 as well as GABA metabolism.25 The
resident macrophage of the retina is the microglial cell. The retina is a region of immune
privilege protected by the BRB to hinder the movement of pathogens and microbes into
the highly sensitive neural retina. Microglia cells act as part of the innate immune system
and partake in immune survelliance35, neuronal support36 and phagocytosis of cellular
debris and pathogens.37 Under necrotic or apoptotic pathways, cellular debris such as
ATP, uric acid and other alarmins are released and stimulate the innate immune system.38
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Microglial cells become activated and elicit an inflammation response to clear cytotoxic
debris from the retina. Together, these three types of glial cells all play a vital and distinct
role in the retina to maintain homeostasis and proper retinal function.

1.6 Retinal neurons rely heavily of oxidative phosphorylation for ATP generation
Neurons of the retina require high amounts of ATP to maintain ionic potentials
through the active transport of Na+ influx and K+ efflux by Na+K+ATPases.39 In addition,
the continuous recycling of neurotransmitters places additional metabolic pressure on the
cell.40 Neurons do not store glycogen and suppress the enzymatic machinery to
synthesize glycogen and therefore rely on the constant flow of oxygen and glucose from
the vasculature in order to maintain their high metabolic rate.41,42 Dendrites, regions of
frequent membrane hyperpolarizations/depolarizations and ion mobility, are the most
energetically consuming region of the neuron. Consistent with their great metabolic rate,
neurons rely heavily on glucose oxidative phosphorylation (OXPHOS) for ATP
production.43–45 Glial cells, on the other hand, are highly glycolytic. In addition, glia also
have the ability to store glycogen and convert it to glucose 6-phosphate when glucose
supply to the retina is diminished.44 Glial cells can provide lactate and other metabolites
to the neurons of the retina via Monocarboxylate transporters (MCT) when glucose
supply is diminished.40
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1.7 Nourishment in the retina is maintained by a healthy blood-retinal-barrier
Glucose is supplied to the retina through the choroid (located posterior to the RPE)
and the retinal capillaries.7 Glucose must first traverse the epithelial barrier of the RPE
(outer BRB) or the retinal capillary endothelial vasculature (inner BRB) which controls
the exchange of metabolites and waste products between the vasculature and neural
retina.46 The inner BRB supplies nutrients and oxygen to the ONL, INL, and GCL,
whereas the outer BRB is responsible for neuronal support of the inner and outer
segments of the photoreceptors.46 Pericytes surround the endothelial cells and secrete
angiopoietin 1 to induce tight junction protein expression.47 Both the inner and outer
BRB develop junctional complexes between the vascular endothelial/epithelial cells to
allow limited movement of ions and solutes into the neural retina.46,48 Tight junctions are
made up of transmembrane proteins known as, claudins, occludin and the junctional
adhesion molecules which are linked to the cytoskeleton of the adjacent cells.46 Tight
junctions lead to the fusion of two adjacent endothelial or epithelial cells and limit
intracellular space to reduce diffusion of ions, pathogens, lipids, proteins, reactive oxygen
species (ROS) and foreign substances into the sensitive neuronal space. Epithelial cells of
the RPE act as a regulatory interphase between the choroid and outer retina. The basal
surface of the RPE contains many invaginations to enhance selective transport and
secretion along the vasculature.15 Due to the continual active transport of substrates
across the RPE and vasculature barrier, cells are highly metabolic and subsequently
require high levels of ATP to maintain efficient transport. The endothelial/epithelial
structure of the BRB is considered to be the first line of defence to protect the neural
retina from invasion of pathogens as they can engulf foreign antigens.15 In addition,
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epithelial cells of the RPE can excrete various cytokines to initiate an inflammatory
response.49 Dysfunctions of the BRB are associated with DR as the dysfunction leads to
pathological changes such as chronic inflammation and hypoxia triggering retinopathy
progression.50,51 In addition, the outer BRB harbours the choroid vasculature and limits
neovascularization in the retina. A loss of integrity also leads to AMD and subsequent
vision loss.

1.8 Electrophysiological examination can assess health of the visual system in vivo
Electroretinography can be used to assess the integrity of phototransduction in the
retina. The electroretinogram (ERG) is a massed, retinal response measured by corneal
electrodes following a light stimulation. The major components of the ERG include, the
a-wave and the b-wave with high-frequency oscillations known as oscillatory potentials
(OP) on the ascending limb of the b-wave (Figure 1.2).11 The initial output wave, known
as the a-wave, is associated with photoreceptor hyperpolarization.52 The secondary wave,
known as the b-wave, is associated with the depolarization of bipolar cells and Müller
cells.53 The exact origin of the oscillatory potentials remains unknown, although they are
believed to be generated by interactions between amacrine, bipolar and ganglion cells.54–
56

Electroretinography can be used to assess the function of both rod- and cone-based

systems. “Dark-adaptation” of the subject prior to the assay will result in rod
hyperpolarization following a light stimulus.57 “Light-adaptation” of the subject prior to
the assay will result in hyperpolarization of the cone photoreceptors as the rods will be
saturated.57 Electroretinography performed under scotopic conditions assesses the
functionality of rod photoreceptors and can be used to examine the inner retinal pathways
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Figure 1.2. A schematic representation of a trace electroretinogram elicited by a
healthy, dark-adapted mouse retina following a light stimulus of 30 cd•s/m2 (Flash
11). All major characteristic components of the electroretinogram are evident. The awave represents the initial hyperpolarization of the photoreceptors and is the initial
negative deflection. This is followed by the intermediate oscillatory potentials (OP) peaks
1-4 (OP1, OP2, OP3, OP4) on the ascending limb of the b-wave. It is apparent that early
OP peaks are correlated with the function of the photoreceptors whereas late OP peaks
are indicative of ganglion and amacrine negative feedback in the outer retina.56 The final
component, the b-wave, represents the depolarization of the bipolar and Müller cells, and
is the cumulative response of the retina.
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and mechanisms rods initiate. Since the mouse retina is composed of well over 97% rods
58

ERGs performed under scotopic conditions provide a more general, comprehensive

analysis of retinal function and health. The ERG provides the only non-invasive, in vivo,
diagnostic tool that can be used to quantify retinal health by testing functionality of
photoreceptors and neural cells of the retina.

1.9 Oscillatory potentials can provide early in vivo examination of INL and GCL
function
Oscillatory potentials (OPs) are the low amplitude, high-frequency oscillations that
are found on the ascending limb of the b-wave.11 The exact origin of OPs remains
unknown and their interpretation remains difficult, however attritional changes are
associated with diseases of the retina particularly retinopathy and retinal degeneration.
Early OPs are believed to be associated with the hyperpolarization of the photoreceptors
and intermediate OPs with action-potential (graded) independent neurons such as
horizontal cells and bipolar cells.56 Later OPs however, are associated with more
proximal retinal responses, that of action-potential dependent mechanisms of amacrine
and ganglion cells.56 Due to the fact that OPs appear as oscillations on the leading edge of
the b-wave, it has been suggested that OPs may be the result of neurons with large lateral
mobility in the IPL i.e. amacrine cells.54,59 Additionally, the interplexiform cell which
spans the OPL and IPL may also generate radial current (feedback) from lateral synapses
and may be responsible for the oscillations.54,55 OPs have been used previously, to study
the function of the inner retina and have been useful in the diagnosis of a variety of
progressive retinal eye diseases including; increased intraocular pressure, diabetic
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retinopathy, retinal vascular occlusions, and retinopathy of prematurity.59–66 OPs have
been useful in the diagnosis of DR prior to any structural cell loss or ocular symptoms in
both human and animal models.59,62,65 Therefore OPs can be used as a versatile, disease
tracking, diagnostic tool prior to any structural and noticeable changes.
There is little consensus on the most appropriate method for extracting oscillatory
potentials from the ERG. Signal conditioning is the first step that must be performed for
isolation of OPs from the ERG trace. Current recommendations set by the International
Society for Clinical Electrophysiology of Vision (ISCEV) suggest a simple band-pass
filter applied at 75 to 300 Hz to remove any a-wave contribution or high-frequency
noise.67 In mice, these cut-offs discard most of the rod-driven OPs and are therefore
rarely followed.68–70 The most common method of OP isolation involves a preconditioning waveform to remove any photoreceptor contribution68,71–74 followed by a
fifth order Butterworth transformation with a band-pass of 65 to 300 Hz (Figure 2.2).68–
70,75

The amplitude and latency of each OP wavelet can be analyzed individually or as a

sum in the time domain; or through a fast Fourier transform in the frequency domain.
The underlying goal of any OP examination is to surmise physiological origins of
the parameters or to identify a clinically relevant, diagnostic parameter that may infer
disease mechanisms prior to disease onset.76 In the time domain (Figure 2.3), analysis of
individual OP amplitudes is advantageous because the amplitudes offer implicit
information about associated retinal regions given retinal layers and signal transduction
through the retina.60 Summed amplitude of all OPs encompasses a full inner retinal
response of the INL and GCL. Initial latency is a measure of synapsis timing and
periodicity of the INL/GCL retinal response.77 Decreases in both OP summed amplitude
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and initial latencies have found in retinopathy,66,78,79 diabetic retinopathy,63,65 and
glaucoma.61 The time domain analysis of OPs contains relevant information in regards to
individual components and mechanisms occurring in the retina, however until an exact
understanding of OP generation is established only qualitative interpretations can infer
disease. The frequency domain (Figure 2.3) analysis of the extracted OP waveform
following application of a fast Fourier transform is advantageous because it provides a
holistic examination of the OP waveform, particularly when signal-to-noise ratio is
low.66,76 In addition, the frequency domain analysis is much more objective as it does not
require the subjective identification of individual OPs which may become troublesome
when signal response is low or noise is high.80 Since both time- and frequency-domain
analysis provide distinct information about OP parameters and general health of the
retina, they were both examined in our investigation to identify an early diagnostic
feature of retinal degeneration.

1.10 Nonmetric multidimensional scaling as a method for understanding OP
waveform changes
In general, the mammalian ERG contains five OP wavelets existing on the leading
edge of the b-wave, each with its own characteristic period (latency) and amplitude.54 OP
profiles depend on the intensity of the light stimulus, with increasing intensity leading to
increased OP amplitude and decreased latency until retinal phototransduction saturation
occurs.66,74,78 Examination of the OPs occurs following a single high-intensity flash and
subsequent comparisons of latencies and amplitudes of each OP between a disease model
and a healthy control. In addition, summed OP amplitude is useful for understanding
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whole retinal response in the time domain.76,78 Examination of OPs at a single flashintensity has limitations since it may not be useful for understanding complete waveform
changes across multiple stimuli intensities where disease mechanisms may be evident in
retinal neurons only activated under low light intensity. The frequency domain provides
a much more holistic approach to whole OP waveform interpretation; however, similar to
the time domain, this approach can only be examined at a single flash intensity to
examine differences in frequency, power, and energy between a disease model and a
healthy control.66,80,81
To understand whole OP waveform changes, a comprehensive nonmetric
multidimensional scaling (NMDS) of OP parameters across multiple flash intensities can
be applied. NMDS is a monotonic, numeric, ordination technique that involves spatial
representation of observed variables to fitted distances.82–84 The method involves the
assignment of derived coordinates for every sample and mandates that rank order may
not be changed but observed proximities can be adjusted.82–84

In this way, many

variables can be examined for each sample and modelled into a previously selected
explicit number of axes, provided that the original rank order is not changed.82 Stress is a
measure of how well the ordination fits the observed distances among samples and the
error associated with modelling.85 Stress increases with the number of samples and the
number of variables fit into the ordination.
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1.11 Mitochondrial dysfunction is a common theme in retinal degeneration
The mitochondrion is the organelle responsible for oxidative phosphorylation
(OXPHOS). In highly metabolic tissues, the density of mitochondria tends to be much
higher to keep up with the energetic demands of the cell.86 The visual pathway is amongst
the most energetically demanding processes in the body, as it requires continual
movement of ions across membranes for maintenance of resting potentials in addition to
the continual recycling of neurotransmitters.87,40 Due to the persistent energetic demands
of the retina, it has the highest relative oxygen consumption of any tissue in the body,
necessary to facilitate OXPHOS.88,89 Therefore, adequate and consistent delivery of
oxygen is vital to retinal homeostasis and any deviations can lead to mitochondrial
dysfunction and subsequent oxidative stress. Mitochondrial dysfunction is a common
theme in retinal degenerative diseases and has been implicated in AMD, OAG, and DR
due to oxidative damage of photoreceptors.90

1.12 The mouse is a valuable model organism for vision research
The use of animal models continues to be vital as an ethical means to investigate
fundamental biological principles. Mouse models are amongst the most common due to
their short life cycle, quick sexual maturity, large litter size, and similar physiological and
genetic composition to humans.91 In addition, isogenic, inbred strains reduce variation
amongst individuals and allow complex diseases to be studied with smaller sample sizes
while achieving higher power to detect significant differnces.11 Many similarities exist
between the human and mouse eye; including a large cornea and lens’ as well as
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analogous retinal nerve layer physiologies and cell types.92 The mouse retina is quite
similar to the human retina with only minor differences in the visual pathway. For
example, mice have a higher proportion of rod photoreceptors (over 97%)58 which makes
their retinas much more effective in scotopic light. Another major difference is the
presence of a macula in the human retina. The macula is a dense, cone-rich area in the
central region of the retina responsible for central vision acuity.7 In mice this is replaced
with a central region of highly concentrated rod photoreceptors.58 While humans possess
three types of cone photoreceptors, mice only have two; green- and blue-sensitive.7 This
property, although a major difference, assists researchers because mouse “dark-adapted”
experiments can be performed in red-light. While subtle differences do exist between the
mouse and human retina, common physiologies, genetics and cell types as well as the
progression of similar diseases make mice an excellent mimic for human retinal disease
mechanisms and subsequently vision research.92

1.13 The harlequin (hq) mouse is a model of mitochondrial dysfunction and
neurodegenerative disease
The harlequin (hq) mouse (XhqXhq, XhqY or XhqX) is a model of mitochondrial
dysfunction associated with neurodegenerative disease of the retina and cerebellum.93
The term “hq” refers to the hqY genotype unless otherwise specified. Characteristic
markers of the hq phenotype include; low body mass, a patchy coat, ataxia, low
subcutaneous fat reserves as well as characteristic retinal and cerebellar degeneration.93
These phenotypic characteristics are the result of a spontaneous proviral insertion into
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intron 1 of the X-linked Apoptosis-inducing factor (Aif) gene which encodes a
mitochondrial flavin adenine dinucleotide-dependent oxidoreductase.94 Since the proviral
insertion is in a suspected regulatory region of intron 1, there is an overall global
downregulation of AIF by nearly 80% in most tissues.93
As described previously, AIF is located on the human X-chromosome in the Xq2526 region.94 The gene is syntenic in the mouse and is also located on the X-chromosome
in the A6 region.94 The AIF amino acid sequence is highly conserved in both organisms,
sharing 92% sequence homology of the active domain as well as an amino-terminal
mitochondrial-localization sequence.94 Upon translocation to the intermembraneous space
of the mitochondrion, the localization sequence is cleaved leaving a functional 57 kDa
flavoprotein.94 AIF is ubiquitously expressed across most tissues in mice95 with
demonstrated embryonic lethality at day 9 in a complete Aif mouse knockout.96 This
indicates AIF’s vital role in development as well as cell life and death.
The function of AIF was first characterized as a mitochondrial bound caspaseindependent death effector protein that translocates to the nucleus and aids with
chromatin condensation and DNA fragmentation when apoptosis is induced.94,97
However, recent investigations have led to the description of multiple functions of AIF.
AIF’s primary role in vivo may be linked to OXPHOS efficiency, particularly that of
NADH dehydrogenase (complex I). Aif-knockdowns have displayed limited formation of
complex I in vivo indicating its role in maintenance and facilitation of complex I
formation.98 hq mice have an overall decrease in mitochondrial complex I efficiency,
particularly that of the retina (~30% of normal function) and brain (~60% of normal
function).95 Although Aif causes a decrease in complex I function, no changes in the
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transcriptome or proteome indicate dysfunction of complex I subunits posttranslationally.98 Further analysis of AIF indicates that it shares sequence similarities94
and similar crystal structure99,100 with bacterial oxidoreductases and may function as a
mitochondrial scavenger of free-radicals including ROS. hq mice demonstrate elevated
oxidative stress in dying neurons of the retina and cerebellum.93 However, this function
of AIF remains controversial because mitochondria isolated from brain of hq mice show
no traces of increased ROS production as a result of Aif deficiency.101

1.14 Timeline of the hq disease progression
Since Aif is mapped to the X-chromosome, affected hq males are hemizygous for
the proviral insertion. Females can either be homozygous or heterozygous for the proviral
insertion. Homozygous females demonstrate a severe, early-onset disease phenotype,
similar to that of hemizygous males.93 Heterozygous females however, show delayed
onset, moderate disease progression and moderate disease phenotype,102,103 likely due to
random X-inactivation.
The progression of the hq disease (homozygous and hemizygous) is well
characterized in both the retina and the cerebellum. The hq disease is an ageingassociated retinal degeneration with primary structural losses occurring as early as three
months of age in amacrine and ganglion cells.93 The progression of the hq disease is
quite rapid with histological analysis indicating significant losses in the INL and ONL by
four months of age.19,93 Examination of the IPL and OPL in the hq retina indicate losses
of neurites, particularly that of dendrites.93 Functional deficits precede structural losses in
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the hq retina with electroretinography showing rapid functional deficits in ERG a-wave
amplitudes at three months and b-wave at two months of age.19 By ten months of age, hq
mice elicit no functional response of the retina.93 Physiological changes begin as early as
1.8 months in the hq retina, consistent with a loss of homeostasis and activation of
microglial cells in the IPL104. This is indicative of an inflammatory response and may
contribute to the early structural and functional losses observed. Chronic activation of
microglial cells continues through hq disease progression and leads to microglial
migration into the ONL and GCL by four months of age, consistent with cell losses
observed previously.93,104
The degeneration of the hq cerebellum occurs with a much slower progression in
comparison to the retina.102 Early histological analysis indicates apoptosis in the hq
cerebellum as early as four months of age in granule cell nuclei leading to smaller total
cerebella by seven months.93,105 Loss of over 50% of granule cells was observed by
twelve months of age.93 Purkinje cell loss in the hq cerebellum occurs later in comparison
to granule cell loss initiating at seven months of age.93,105 Characteristic markers of
microglia activation in the hq cerebellum have yet to be tracked in situ.

1.15 Deficiencies in OXPHOS lead to neuronal malfunction and ATP deficiencies
It is well established that OXPHOS is the major source of ATP for all cells, in
particular neuronal cells of the brain and retina. Energetic failure of OXPHOS in
neuronal cells has been linked with Alzheimer’s disease,106 Parkinson’s disease,107
Huntington’s disease,108 amyotrophic lateral sclerosis109 and other neurodegenerative
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disorders. Neuronal cells maintain consistent internal ATP concentrations and minimal
energy gradients by axonally transporting mitochondria via microtubules to regions of
high energy consumption.110 The presynaptic compartment of the neuron, responsible for
neurotransmitter release, is the region of highest energy consumption.110,111 High amounts
of ATP are required for continuous neurotransmitter recycling as well as ion pumping to
maintain membrane potentials.111 Deficiencies in OXPHOS particularly affect the
presynaptic cleft and other highly metabolic regions leading to neurite loss and synaptic
degeneration.111,112
In addition to being “the powerhouse of the cell,” the mitochondrion is also an
intracellular regulator of calcium. Mitochondrial dysfunction as a result of OXPHOS
deficiency causes mitochondrial overload of Ca2+, leading to opening of the
mitochondrial permeability transition pore and Ca2+ release.113,114 This furthers induces
ATP deficiency, successive glycolytic ATP dependency, reduced mitochondrial mobility,
release of ROS and subsequent activation of the caspase execution cascade leading to
apoptosis and cell death in the tissue.114–116

1.16 OXPHOS deficiencies in the hq mouse
The variability associated with the hq disease phenotype is large, with timing of
disease onset and progression occurring differently across individuals.95 Additionally, the
effect of the Aif proviral insertion is also not equivalent across tissues of the hq mouse.
Western blotting reveals that AIF expression in hq mice, in comparison to controls, was
approximately 20-40% in the cerebellum, spinal cord, cortex, skeletal muscle, and
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kidney.95 AIF reaches almost 60% expression levels in the liver, with minimal to nil
expression in the retina.95
In association with decreased AIF expression, compromised OXPHOS efficiency
was found in all regions of the brain and retina however no OXPHOS deficiency was
evident in the heart or the liver.98 A complete knockout of Aif in the mouse heart does
however lead to reduced OXPHOS activity indicating the buffering threshold of the Aif
knockout may be organ specific.117 Tissue specific Aif knockout for liver, muscle and
heart leads to increased glucose uptake (via glucose transporter 1 and 4) as well as a
reduction in overall ATP levels and high NADH/NAD+ ratios and lactate production.
This suggests the switch towards glycolytic metabolism and generation of anaerobic
ATP.117,118 In addition, hq mice demonstrate similar characteristics of increased insulin
sensitivity and glucose uptake/tolerance with reduced predisposition to obesity on a high
fat diet.118
The complete Aif

knockout in embryonic stem cells identifies consistent

consequences leading to high levels of lactate production.98 The addition of 2-Ddeoxyglucose, an inhibitor of glycolysis, increases apoptosis in these Aif-deficient
embryonic stem cells and indicates high dependency on glycolytic ATP and glucose as a
primary metabolite.98 Taken together, this thorough examination of AIF dysfunction
indicates a metabolic change towards anaerobic and lactate ATP production in Aifdeficient cells particularly in tissues of mesodermal and ectodermal origin.
The knockout or knockdown of Aif predisposes embryonic stem cells, muscle, liver
and heart cells to mitochondrial OXPHOS deficiency and reduces overall ATP
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generation. Aif–deficient cells must compensate and switch their metabolic processes
towards a glycolytic pathway of ATP production and promote high glucose uptake and
metabolism. Glycolysis is the conversion of a glucose molecule into pyruvate in a 1:2
ratio with the reduction of two NAD+ molecules to NADH and the net overall production
of two ATP molecules. The switch to glycolysis allows for ATP production when
OXPHOS is an inefficient source of energy production and provides the necessary energy
for metabolic need. Unlike other cell types and tissues, glycolysis is intrinsically
repressed in neurons and the central nervous system to maintain low oxidative stress.45,119
Therefore they do not have the ability to increase glycolysis when OXPHOS integrity is
interrupted.45 PFKFB3 enzymatically produces fructose-2,6-bisphosphate (a strong
glycolytic activator) and is down-regulated in neurons. Its overexpression leads to
oxidative stress and cell death in vivo.45 Since neurons of the central nervous system rely
almost completely on OXPHOS-generated ATP, they are highly vulnerable to decreases
in ATP generation.120 In the hq mice, this is evident due to the severe and irreversible
onset of retinal and cerebellar degeneration.

1.17 Parainflammation is a chronic response in the hq retina
Inflammation is the biological response to maintain homeostasis following a
negative insult in vivo. Inflammation is commonly the product of a tissue injury or
infection121 and solicits the homeostatic response of the innate immune system and the
adaptive immune system. The recognition of pathogens by the innate immune system
begins with the specific binding of the pathogen-associated molecular patterns (PAMPs)
expressed by microbes via Pattern Recognition Receptors (PRP)122. Following binding,
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immune cells (macrophages) are recruited and the pathogen is destroyed and removed.
The adaptive immune response is triggered for the selection of an antibody to better
target the pathogen during future insult. In the event of a tissue injury, the innate immune
system must respond to cellular damage of an endogenous injured cell and therefore
PRPs are not present. The response to these injuries is facilitated by endogenous
molecules known as alarmins that are released during non-programmed cell death and
recruit the innate immune response.123,124 One such example is that of architectural
chromatin protein, High Mobility Group Box 1 (HMGB1).125 Under apoptotic conditions
HMGB1 binds irreversibility to nucleosomes and elicits no immune response, however
under necrotic conditions HMGB1 is released into the extracellular space and becomes a
potent activator of inflammation.125
In addition, alternative endogenous mechanisms beyond necrosis can induce
inflammation. The formation of advanced glycation end-products (AGEs) begins under
hyperglycemic or oxidative conditions and catalyzes the interaction of glucose with
protein amino acids and lipids.126 Once formed, they bind with the receptor for advanced
glycation end-products (RAGEs) which can induce a pro-inflammatory response through
the secretion of Tumor necrosis factor α (TNF-α) and stimulation of T-cells.126 Under
oxidative conditions; proteins, lipids and DNA can be oxidized. Lipids are oxidized into
highly reactive aldehydes which in turn induce macrophage secretion of TNF-α and elicit
an inflammatory response.127 Finally, inflammatory cytokines released by activated
macrophages can further induce inflammatory responses. Chronic cytokine release by
macrophages causes further tissue damage and the potential breakdown of blood
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barriers.121 Inflammatory cytokines can alter the functionality of the endothelial/epithelial
tight junctions leading to barrier degradation.128
Microglial cells are the resident macrophages of the retina and cerebellum that are
responsible for the innate immune response during an inflammatory stimulus.12 Resting,
dormant microglia cells generally take on a ramified cellular morphology with many
protrusions as a means to monitor their microenvironment as well as clearing any
metabolic waste and tissue debris.129 Microglial cells become activated during neuronal
injury, stress and infection changing their cell morphology to an amoeboid macrophage.
The surface membrane, G-coupled purinergic membrane receptor P2Y12 can detect small
changes of ADP and ATP concentrations in the extracellular space released by stressed or
necrotic neurons and prompts microglial activation.130 Activated microglia become
highly mobile and exhibit strong phagocytic ability and further induce the release of
cytokines to enhance microglia recruitment to mediate tissue repair.121 During healthy
conditions, this is generally a low-grade tissue adaptive response known as basal
inflammation. In contrast, chronic activation of microglia cells as a result to neuronal
stress can lead to a state of parainflammation. Parainflammation is an intermediate
response between overt-inflammation and non-inflammatory removal of apoptotic
cells.121 Chronic microglial activation is associated with the release of tissue damaging
ROS, nitric oxide, proteases, and further cytokines causing exaggerated recruitment of
microglial cells and retinal degeneration.131 Parainflammation and chronic microglial
activation have previously been observed in the hq retina as early as 1.8 months of age as
a result of AIF downregulation. Chronic microglial activation may be the cause of
subsequent structural losses in the hq retina. The exact triggers leading to chronic
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microglial activation has yet to be defined and may be the result of a continuous
endogenous stress (tissue stress) or the breakdown of a retinal barrier allowing chronic
influx of exogenous pathogens into the sensitive retinal space (Figure 1.3).

1.18 Central hypothesis
I hypothesize that since the hq mouse is hypomorphic for AIF function in oxidative
phosphorylation, health of the inner retina is compromised without loss of blood-retinalbarrier integrity and evidence of compensatory ATP production mechanisms exist.

1.19 Experimental Aims
The first experimental aim is to determine if electroretinogram oscillatory
potentials can infer early mechanisms of retinal degeneration, particularly operational in
the inner retina. The use of OPs as a non-invasive diagnostic feature could infer
physiological changes as well as the health of the inner retina prior to any cell losses. The
rapid onset of the hemizygous hqY disease leads to functional losses as well as later
structural losses. OPs have been used to track disease progression prior to any
symptomatic functional losses in a variety of retinal diseases as OP features infer the
health of various neural networks in the retina. It is therefore predicted that OPs can be
used to diagnose early functional changes in the hq retina prior to any structural losses.
To track and examine disease progression, OP from hq mice were analyzed monthly from
two months of age to ten months of age. This provides long term disease progression
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information and functional retinal documentation at a later age. To complement the
examination of OPs in the severe and rapid disease phenotype, the investigation of the
heterozygote phenotype can provide valuable information regarding disease progression.
Female heterozygotes demonstrate a longer timeframe to observe disease mechanisms
prior to cell death and were examined at three months, eleven months and fifteen months
of age.
The second experimental aim is to assess RPE (outer BRB) and inner retina
endothelial vasculature barrier (inner BRB) integrity to ascertain the potential for
exogenous triggers of microglial activation and subsequent retinal degeneration (Figure
1.3). This examination is instrumental in determining if the metabolic deficiency
associated with hq neurons compromises the functionality of the highly metabolic RPE
and inner retina endothelial vasculature barrier. Metabolic deficiency in the hq retina may
result in the degradation of tight junctions and lead to vascular endothelial/epithelial
leakage into the sensitive inner retinal space and thereby elicit microglial activation.
Alternatively, it can be hypothesized that microglial activation in the hq retina is the
consequence of endogenous photoreceptor and inner retinal neuron cell stress due to ATP
deficiency triggering chronic microglial activation. To examine the integrity of the BRB,
injections of Evans Blue followed by a complete vascular perfusion assesses diffusion of
albumin-bound Evans Blue into the inner retina and potential breakdown of the BRB.
Two age groups of mice were examined for both wild-type and hq mice: a younger age
group (< 4 month) prior to ONL losses, and an older age group (> 7 months)
corresponding to chronic microglial activation at 1.8 months. It is hypothesized
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Figure 1.3. Activation of retinal microglia may be the result of blood-retinal-barrier
breakdown (exogenous) or inner retinal dysfunction (endogenous). (A) Microglia
activation (ramified to amoeboid) may be a consequence of BRB breakdown causing
diffusion of harmful exogenous antigens into the sensitive retinal space. Highly metabolic
epithelial and endothelial cells of the BRB may malfunction due to intracellular ATP
deficiency. (B) Alternatively, microglia activation may be the result of internal neuronal
malfunction due to AIF downregulation and ATP deficiency leading to cell stress,
apoptotic and necrotic conditions thereby inducing parainflammation and chronic
microglia activation.
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that microglial activation in the retina is the result of endogenous ATP deficiency leading
to cellular stress and apoptotic neurons rather than a compromised BRB inducing
microglial activation.
The third and final aim is to confirm retinal transcriptome changes consistent with
mitochondrial dysfunction and subsequent metabolic disease during the onset and
progression of hq retinal and cerebellar degeneration. The downregulation and reduced
expression of AIF leads to alternative metabolism in mesodermal tissues. It was predicted
that similar compensating mechanisms were expected to transpire in the hq retina and
cerebellum. Although glycolysis is unlikely to be upregulated in hq neurons, alternative
pathways of ATP production such as lactate production, glycerol metabolism and glucose
uptake are predicted to be upregulated. To confirm transcriptome changes consistent with
alternative metabolism three ages were examined corresponding to disease onset and
progression (two, three and four months of age). Since the cerebellum is not as ATP
demanding as the retina40 and histological changes occur later in the hq cerebellum it is
expected that metabolic changes in the hq mouse are not as evident by four months of
age.
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Chapter 2. Materials and Methods
2.1 Animal care and housing
The Canadian Council on Animal Care and The Animal Use Subcommittee of
The University Council on Animal Care approved all protocols prior to the
commencement of any experimental work (Appendix A). Mice (B6:CBACaAw-J/APcdc8hq/J, 97% CBA/CaJ genetic background) [Jackson Laboratories, Bar Harbor, ME]
were housed at a constant temperature of 21 ± 1oC with a relative humidity of 44% to
60% and a light/dark cycle of 14/10 hours. The mice received a standard diet [PMI
Foods, St. Louis, MO] and water ad libitum.

2.2 Genotyping of the hq allele
A tri-primer polymerase chain reaction (PCR) was used to determine the presence
of the Aif hq allele.93 Tissue samples for genotyping were taken as ear-notches when mice
were approximately 12 days old. DNA was amplified using the TerraTM PCR Direct
[Clontech, Mountain View, CA] standard protocol. Amplified DNA was subjected to gel
electrophoresis through a 1.5% agarose gel stained with SYBR® Safe DNA Gel Stain
[Life Technologies Inc., Burlington, ON]. The presence of a 725 bp amplicon indicated
the Aif hq disease allele and the presence of a 537 bp amplicon indicated a wild-type Aif
allele. Female heterozygous mice show both a 537 bp and a 725 bp amplicon. PCR
primer sequences used for Aif genotyping are provided in Appendix B (Table B.1).
Reference to the hq phenotype refers to the hqY genotype unless otherwise specified.
Wild-type (WT) mice refer to male (XY) mice with a functional Aif.
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2.3 Collection of trace electroretinograms
Repeated electroretinogram (ERG) analyses were performed on cohorts of wildtype mice and hqY mice at two, three, four, five to seven and eight to ten months of age
to assess retinal function and severe disease progression (Figure 2.1A,B).132 Additionally,
ERG analyses were performed on female carrier mice (hqX) along with an age-matched
wild-type cohort at three, eleven and fifteen months to assess moderate disease
progression of the hq carrier disease (Figure 2.1B).102,103 Electroretinography was
performed with a Colordome Stimulator [Diagnosys, Lowell, MA] on both dark-adapted
(scotopic) eyes through a series of eleven flashes of increasing intensities (0.001 – 25
cd•m/s2).

2.4 Processing of trace electroretinogram for waveform modelling
Original exported ERG trace files contained only data corresponding to parameters
of the a-wave and b-wave components. A thorough review of the ERG user manual was
performed and allowed for export of all raw data corresponding oscillatory potential
components. A macro written into Excel [Microsoft, Redmond, VA] known as
“MLTRIM” automatically sorted the original trace file into averaged neuronal responses
for each eye and presented them as µV across all flash intensities.133 In addition,
MLTRIM was used to convert ERG trace data into a format readable by MATLAB [The
MathWorks, Natick, MA].
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Figure 2.1.4Experimental design and cohort sizes for oscillatory potential analysis.
(A) The complete experimental design for the severe disease progression hqY analysis.132
A single mouse may appear multiple times due to repeated measures at multiple ages. (B)
Repeated measures of the severe disease progression experiment were removed randomly
to allow study of hqY mice without repetition. (C) The complete experimental design for
the moderate disease progression hqX experiment.103 No repeated measures were present
in this study.
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2.5 Signal conditioning and oscillatory potential waveform extraction
Scripts (Appendix C, MATLAB Script A,B) were written into MATLAB [The
MathWorks, Natick, MA] to model and extract relevant oscillatory potential waveforms
(Figure 2.2).133 To limit contribution of photoreceptor hyperpolarization, the a-wave was
digitally modelled and subtracted from the original trace (Figure 2.2A).66,68,69,71–74
Additional high frequency and low frequency noise were removed by processing the
waveform through a fifth-order Butterworth filter with a band pass of 65-300 Hz (Figure
2.2C).69,70

Previous literature suggests a lower band pass limit of 40 Hz for

characterization of mouse rod photoreceptor oscillatory potentials, however 65 Hz was
chosen to avoid interference by the 60 Hz line noise as previously described.69,70 The
remaining bandwidth made up the final OP waveform, herein known as the “extracted
waveform”.

2.6 Parameter analysis of the extracted waveform
The extracted waveform was first analyzed in the time-domain. The amplitude
(µV), initial latency (ms) and interpeak distance were determined for OP2, OP3, OP4,
and OP5 (Figure 2.3A). Following waveform extraction, OP1 was typically present,
however due to inconsistencies OP1 was not included in further analysis. Amplitude of
each OP was defined as the difference between the trough and the peak immediately
preceding it (Figure 2.3A). Initial latency was defined as the time from stimulus to the
onset of OP2 (Figure 2.3A). Interpeak distance was the measurement of time (ms)
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Figure 2.25Signal conditioning of oscillatory potentials from the ERG trace
waveform. (A) A digital subtraction of photoreceptor contribution (dashed line) was
performed by a mathematical fitting and subtraction of the a-wave from the initial ERG
(solid line). (B) The ERG waveform following complete a-wave digital subtraction. (C)
The final waveform was passed through a fifth order Butterworth transformation (65-300
Hz) to remove any low or high frequency noise resulting in the final “OP extracted
waveform” (solid line).
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Figure 2.3.6Measurement of individual Oscillatory Potential features in the timedomain and frequency-domain. (A) Following waveform extraction, measurements of
OP latency (ms) and amplitude (µV) were taken for OP2, OP3, OP4, and OP5.
Amplitude of each OP was defined as the difference between the trough and the peak
immediately preceding it. Initial latency was defined as the time from stimulus to the
onset of the OP2 peak. Interpeak distance was the measurement of time (ms) between
adjacent peaks. OP1 was not measured due to inconsistencies and the potential for awave contamination. (B) A fast Fourier transform (FFT) was applied to the extracted OP
waveform and gave a single-sided smoothed frequency power spectrum (dotted Line).
The single-sided smoothed frequency power spectrum was fitted to a two-term Gaussian
envelope (solid line) and measurements of peak power (Ppeak), peak frequency (Fpeak) and
total energy (waveform integration) were taken.
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between adjacent peaks (i.e. OP2 and OP3) (Figure 2.3A). Total OP response in the time
domain was measured as the summation of OP2-OP5 amplitudes.

2.7 Fast Fourier Transformation (FFT) of the extracted waveform
The frequency spectrum of the extracted waveform was also analyzed by a Fast
Fourier Transformation (FFT) to provide a holistic frequency waveform interpretation.54
Scripts (Appendix C, MATLAB Script C) written in MATLAB [The MathWorks, Natick,
MA] performed this operation and converted the frequency-power spectra to a singlesided smoothed frequency power spectrum. To avoid “powers of two” problems, only the
first 128 samples of the extracted waveform (contained entire OP waveform) were
applied to the FFT.66 To calibrate the output of the FFT, a sine wave of known periodicity
and amplitude was subjected to the algorithm. These produced a single peak indicative of
a properly calibrated FFT algorithm. To avoid the problem known as ‘overspill’ the FFT
output was fit to a two-term Gaussian envelope with the following equation: 66,75

( )

(

)

(

)

where P is the power associated with the frequency response (F, Hz). Fpeak is the
frequency at the peak of the Gaussian envelope, and Ppeak is the corresponding power
(Figure 2.3B). Major frequency (Fpeak) was determined as the dominant frequency of the
Gaussian frequency-power spectrum and is related to OP periodicity. S indicates the
width of the time distribution. The area under the original frequency power spectrum
(Total energy) was calculated by integration of the original frequency-power spectrum
(Figure 2.3B).
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2.8 Non-Metric Multidimensional Scaling (NMDS) of oscillatory potential
parameters
The longitudinal nature of the hqY study does not allow simple statistical testing
(Figure 2.1). Approximately five mice were euthanized at the end of each age cohort age
(2, 3, 4, 5-7, 8-10 respectively) and the attrition associated does not allow the application
of a simple repeated-measures two-way ANOVA. In addition, OPs contain a wealth of
information across multiple flash intensities and a comprehensive analysis was pursued
as described in the introduction. A clustering method known as Non-metric
Multidimensional Scaling (NMDS) was used in R Statistical Software [R Core Team,
Vienna, Austria] (Appendix D, NMDS R-code A) to model every variable from each
respective OP peak at all four flash intensities (Flash 8-11). This resulted in a total of 32
variables being analyzed in the time domain and 12 variables in the frequency domain
(Figure 2.4). Each variable was first converted into a z-score using the following
equation:

where x is each value in the dataset, µ is the mean of the dataset and σ is the standard
deviation of the dataset. The Euclidean distance between all mice was calculated
encompassing all variables and a dissimilarity matrix was computed to demonstrate the
absolute distances between mice.82 A NMDS was then applied to model data in a twodimensional ordination plot such that rank order matches the order of dissimilarity
between mice. Stress is indicative of the best rank order of agreement between the
dissimilarities as well as fitting the data to a monotonic regression (Shepard plot). Lowest

45

46
Figure 2.4.7Total number of measurements taken from a single mouse across four
flash intensities. (A) A total of 32 parameters are measured in the time-domain, eight
measurements for each flash intensity. (B) A total of 12 parameters are measured in the
frequency-domain, three for each flash intensity.
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stress was found at the global optima following 100 iterations. Stress below 20% is
deemed fair.82 For NMDS axis interpretation a Pearson’s correlation coefficient was used
to interpret the axis in relation to various time domain and frequency domain parameters.

2.9 Experimental design for Blood-Retinal-Barrier (BRB) integrity phenotyping
Male hqY mice and age-matched wild-type controls were selected at two age
cohorts of two-to-four months of age and seven months of age. The number of mice in
each cohort was between three and five individuals. Evans Blue dye [Sigma Aldrich, St.
Louis, MO] dissolved in 1X Phosphate Buffered Saline (PBS) (50µL) [Santa Cruz
Biotechnology, Dallas, TX] was intravenously injected over 15 seconds through the tail
vein at a concentration of 45 mg/kg.134,135 Following injection, the dye was allowed to
circulate through the vasculature for a period of 30 minutes. During this period the mouse
turned visibly blue particularly in the extremities, confirming the uptake and distribution
of the dye.136 The mouse was then euthanized via CO2 inhalation and the chest cavity was
opened. A transcardial perfusion with 60 mL 1X PBS was performed until all blood was
removed from the vasculature. Tissue was stored at -80oC until further processing.

2.10 Generation of a standard curve to estimate Evans Blue tissue concentrations
A standard curve was generated to calculate concentrations of EB in respective
tissues. Serial dilutions of EB in formamide were made from 10000 ng/mL to 250 ng/mL
and background-subtracted absorbances (620 nm - 740 nm) measurements were made in
triplicate. Standards were prepared on different days by three different individuals.
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2.11 Evans Blue Extravasation
Immediately following PBS perfusion, eyes were enucleated and the retinas were
carefully microdissected away and rinsed with PBS. Liver, cerebellum and cerebrum
tissue were also harvested and rinsed with PBS. Tissues were flash frozen in liquid
nitrogen and stored at -80oC until further processing.
The wet weight of tissues was determined and they were then homogenized using a
blunt homogenizer. The approximate weight of a mouse retina was 1 milligram and
therefore approximately 1 mg of liver tissue was also processed as a technical control. EB
was extracted from liver and retinal tissue by incubating in 100 µL of formamide [Sigma
Aldrich, St. Louis, MO] for 24 hours at 75oC.134 Cellular debris was removed by
centrifugation at 4000 rpm for 45 minutes. Approximately 1 µL of supernatant was used
for triplicate spectrophotometric measurements using the NanoDrop ND-1000
Spectrophotometer [Thermo Scientific, Wilmington, DE]. A background-subtracted
absorbance was determined with measurements at 620 nm and 740 nm, known
absorbance maximum and minimums for EB dye.134 The concentration of the dye in the
extracts was determined using the standard curve and was normalized to liver
concentrations from the same animal to account for technical variation such as albumin
dye uptake and injection efficiencies. Statistical significance was determined using a twoway ANOVA.
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2.12 Examining daily food consumption in the hq mouse
Four-month-old hqY (n = 4) and age-matched, wild-type (n = 4) mice participated
in a feeding study to determine average daily food consumption (grams of food
consumed/ grams of body mass/ day) differences in hq mice. Food intake (mass) and
mouse mass were measured every-other-day over a two-week period to determine daily
food consumption. At the end of the two-week period, average daily food consumption
for each mouse was determined and divided by the mouse mass. Statistical significance
was determined by a repeated-measures ANOVA.

2.13 Microarray pathway analysis
To identify early triggers and mechanisms of retinal degeneration, gene expression
microarray [Affymetrix, Mouse Gene 1.0 ST Array, Santa Clara] data were analyzed
extensively. The microarray data were obtained by Alex Laliberté with 4-month-old hq
and age-matched wild-type mice.103 To determine early mechanisms of retinal
degeneration selection criterion were set; at a significant change of p < 0.05 and a
threshold fold change (mRNA transcript level) of at least ± 1.75. Canonical pathway
analysis was performed using KEGG Pathway Analysis [Kyoto University, Kyoto, Japan]
and Ingenuity Pathway Analysis [Ingenuity Systems Inc., Redwood City, CA]. A
thorough literature review of Aif function complemented this pathway analysis and
indicated a loss of Aif function leads to increased glucose metabolism, lactate
metabolism, as well as glycerol and fatty acid metabolism.98 Due to the specific nature of
retinal degeneration markers and multiple genetic isoforms used in the retina, gene
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ontology databases did not provide a thorough review of microarray data. Therefore
grouping and annotation of differentially-expressed genes was performed manually and
based on extensive literature survey on above pathways in NCBI [National Institute of
Health, Bethesda, MD] (Appendix E). Multiple genes (>1.75 fold change, p < 0.05) from
each above stated pathway were selected for confirmation of transcriptome changes via
quantitative PCR (qPCR).

2.14 Tissue harvest for gene expression assays
Cohorts of hqY mice aged two-, three-, and four-months of age and age-matched
wild-type mice (n = 5 per cohort) were euthanized via CO2 inhalation according to
Animal use Protocol (AUP) 2009-033 (Appendix A). Eyes were enucleated and retinas
were microdissected and cleaned with 1X PBS in an RNase-free environment.
Cerebellum, cerebrum and liver tissues were also harvested. Extracted retinas and
cerebella were flash frozen in liquid nitrogen and stored at -80oC. All tools involved in
microdissection were baked overnight at 200oC or treated with RNaseZAP [Sigma
Aldrich, St. Louis, MI] to ensure an RNase-free environment and RNA integrity.
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2.15 Retinal RNA extraction
Retinal samples (~1 mg) were homogenized and lysed using a sand
homogenization protocol as previously described.137 Ottawa Sand (20-30 mesh) [Fisher
Scientific, Fair Lawn, NJ] was rinsed through multiple, serial washes of ddH2O, 0.5M
NaOH and 0.5M HCl and baked overnight at 200oC. Following homogenization, RNA
was isolated using the Qiagen® RNeasy Mini Spin Columns Kit [Qiagen Canada Inc.,
Montreal, QC]. This included binding of total RNA to a silica membrane within the spincolumn. A series of subsequent RPE® and RW1® washes were performed to clean the
RNA and increase efficacy of RNA binding to the silica column membrane. An oncolumn Qiagen® RNase-Free DNase [Qiagen Canada Inc., Montreal, QC] step was
performed to remove genomic DNA (gDNA) contamination. RNA was resuspended in
nuclease-free ddH2O and stored at -80oC.

2.16 Cerebellar RNA extraction
Cerebellar samples (30 mg) were lysed with Qiazol® Lysis Buffer [Qiagen
Canada Inc., Montreal, QC] and were homogenized by 20 strokes in a 7 mL Type A
Glass Dounce Homogenizer [Wheaton Science Products, Millville, NJ]. Following
homogenization, total RNA was isolated using the standard protocol for the Qiagen®
RNeasy Mini Spin Column Kit [Qiagen Canada Inc., Montreal, QC] as described above.
An additional on-column RNase-Free DNase step was added and RNA was resuspended
in nuclease-free ddH2O and stored at -80oC.
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2.17 Assessment of RNA purity and quality
Retinal and cerebellar RNA quality was first assessed with a NanoDrop ND-1000
Spectrophotometer [Thermo Scientific, Wilmington, DE] to determine A260/A280 ratios
(>1.9). Cerebellar samples were then subjected to gel electrophoresis and electrophoresed
through a 1.5% agarose gel to determine the presence, integrity and ratios of the 18S and
28S rRNA subunits. This quality assurance stage was not performed with the retinal
samples as the total amount of RNA isolated was considerably lower and not sufficient to
perform gel electrophoresis. However, to ensure RNA purity, both cerebellar and retinal
samples (1 µL) were assessed with the Agilent 2100 Bioanalyzer [Agilent Technologies
Inc., Palo Alto, CA] to determine RNA integrity (RNA Integrity Number - RIN > 8).

2.18 cDNA synthesis
Mouse retinal RNA samples were selected for single-stranded, complementary
DNA (cDNA) synthesis from concentrations ranging from 15 ng/µL to 72 ng/µL. Mouse
cerebellar samples were selected for cDNA synthesis from concentrations ranging from
84 ng/µL to 354 ng/µL. In each age cohort, the lowest concentration was selected as the
rate-limiting sample, indicating the highest total RNA (µg) that could be added to the
cDNA synthesis reaction based on the final volume of 16 µL. cDNA synthesis was
performed using the Superscript® VILOTM cDNA Synthesis Kit [Life Technologies,
Burlington, ON] and its associated standard protocol. A negative control did not contain
any RNA and ddH2O was used as a substitute. Following synthesis, cDNA was diluted to
100 µL to increase downstream throughput and stored at -20oC.
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2.19 Taqman ® gene expression experimental design
qPCR was performed using Taqman® probes [Life Technologies, Burlington, ON].
Probes that spanned exon junctions were selected to avoid the possibility of false
amplification due to gDNA contamination. Genes were assayed in a block design for
each age cohort (Appendix B, Figure B.1). Each gene of interest was assayed in three
technical replicates including triplicate No-Template Controls (NTC). Biological
replicates were assayed in parallel to avoid the possibility of additional technical
variation (n = 4). For each reaction; 5µL of Taqman® Fast Advanced MasterMix [Life
Technologies, Burlington, ON], 0.5 µL of Taqman® probes [Life Technologies,
Burlington, ON], 2.5 µL of nuclease free water and 2 µL of cDNA were added to a final
volume of 10 µL per reaction well. The assay was performed using the ViiATM 7 RealTime PCR System [Life Technologies, Burlington, ON]. qPCR cycling conditions began
with a 2 minute hold at 50oC for Uracil N Glycosylase incubation, a 20 second hold at
95oC for complete cDNA denaturation, followed by 40 cycles of 1 second at 95oC for
denaturation and 20 seconds at 60oC for primer annealing and polymerase extension.
Two reference genes, 18S Ribosomal RNA (Rn18s) and Glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) were selected as normalizer genes due to their documented high
and consistent expression levels in all tissues.138,139 Rn18s was selected to ensure
expression of Gapdh was consistently expressed between hq and wild-type mice. Upon
confirmation of high, consistent uniform expression of Gapdh across genotypes, Gapdh
was selected as the primary normalizer. Aif was assayed across all cohorts to ensure a
downregulation in hq mouse retina and cerebellum.
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2.20 Statistical analysis of Taqman ® gene expression changes
The ΔΔCt relative quantification method was used to determine fold-changes
across genotypes.140 ΔCt values were determined as the difference between the measured
average amplification cycle of the gene of interest and the average amplification cycle of
Gapdh. Significance was determined with a one-way ANOVA in Excel [Microsoft,
Redmond, VA] comparing ΔCt values between hq and wild-type mice in each cohort. To
calculate fold-change the hq ΔCt values were subtracted from wild-type ΔCt values to
yield a ΔΔCt value which was then input in to the following equation to determine fold
change:
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Chapter 3. Results
3.1 Mouse phenotyping and Aif PCR genotyping confirmed the presence or
absence of an Aif proviral insertion
Characteristic phenotypic hq markers such as a patchy coat, ataxia and low body
mass were consistently observed among XhqXhq and XhqY mice. Genotypes of mice used
in this study were confirmed by PCR using the tri-primer method. A 725 bp amplicon
indicated the presence of an Aif hemizygous males (hqY) proviral insertion whereas the
presence of a 537 bp amplicon indicated a wild-type Aif allele (Figure 3.1). Female
heterozygotes (hqX) showed amplification of both 537 bp and 725 bp amplicons (Figure
3.1).

3.2 hqY mice show longer latency as early as three months and progressive
decreases in OP summed amplitude following a 10 cd•s/m 2 stimulus
Time-domain analysis of ERG OPs revealed no early (two month) delays of initial
OP latency in hq disease mice when compared to the wild-type mice (Figure 3.2A).
However, by three months of age hq mice demonstrate a significant delay (p = 0.005,
Figure 3.2A) of initial OP latency by 24.6%. This is indicative of neural retinal feedback
delay between the photoreceptors, INL and GCL of the retina. The trend of OP delayed
response continues at four months and is significantly delayed at five to seven months (p
= 0.0115, Figure 3.2A). Summed OP amplitudes demonstrated no significant changes at
two or three months of age in the hq mice indicating normal INL and GCL function
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Figure 3.1.8PCR amplification confirmed Aif genotype. Aif genotyping PCR
amplicons were electrophoresed through a 1.5% agarose gel and stained with SYBR ®
Safe DNA Gel Stain (Invitrogen, Burlington, ON). A 100 bp DNA ladder (FroggiaBio
Inc, Toronto, ON) was used as a size standard (STD) to estimate amplicon size. A single
537 bp amplicon indicated a wild-type Aif allele (XY) while a single 725 bp amplicon
indicated the presence of an Aif proviral insertion.93 Heterozygote, hq carriers
demonstrated the presence of both 537 bp and 725 bp amplicons. A no DNA control
(NC) was created with water prior to amplification and added to the PCR mastermix to
eliminate the possibility of a false positive.
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(Figure 3.2B). However by four months of age, a significant deterioration of summed OP
amplitudes (p = 0.0222) by 26.5% occurred in hq mice resulting in reduced INL and GCL
function (Figure 3.2B). The largest effect on summed OP amplitudes occurred at five to
seven months with a significant reduction (p = 0.003, Figure 3.2B) by 54.4%. No
statistical conclusions can be made about initial OP latency or summed OP amplitudes at
eight to ten months of age as the hq cohort only contains two mice, although general
trends appear to continue (Figure 3.2A,B).

3.3 Frequency-domain analysis of ERG OPs show early frequency changes in hqY
disease mice followed by later changes in OP power and energy (10 cd•s/m 2 stimulus)
hqY OP frequency demonstrated early, two-month changes with a significant
reduction by nearly 14% in comparison to the wild type. Significant reductions were also
present at three (p = 0.0015, 26.6%) and four months (p = 0.0248, 25.9%) of age (Figure
3.3A). This is indicative of delayed periodicity and reduced neural feedback mechanisms.
hqY overall OP power showed no early significant changes at two, three, or four months
in comparison to the wild type (Figure 3.3B). This indicated adequate uniform retinal
response of the INL and GCL of the hq mice. However by five to seven months of age,
overall OP power demonstrated a significant reduction (p = 0.0028) by nearly 54.5% in
comparison to the wild type (Figure 3.3B). Total OP waveform energy, indicative of total
retinal INL, GCL and retinal response across the entire retina, demonstrated no early
changes at two or three months of age in hqY mice (Figure 3.3C). A significant decline
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Figure 3.2.9Electroretinography demonstrates delayed retinal responses and
decreases in initial OP latency followed by subsequent reductions in summed OP
amplitudes in the hq retina following a 10 cd•s/m2 stimulus. (A) Initial latency of OP2
indicates the functional response of the INL and GCL cells to photoreceptor
hyperpolarization. Delayed initial latency of OP2 is evident at three months in hq mice
with a significant delay of nearly 24.6% in comparison to the wild type. The delay in hq
initial OP response is also evident at five to seven months with an overall delay by
30.8%. (B) Summed amplitude is indicative of the overall retinal response and continuity
of neural feedback of the INL and GCL. Significant reductions in hq OP summed
amplitude are first apparent at four months of age resulting in an overall reduction by
nearly 26.5%. In five-to-seven-month-old hq mice, the disease reduces summed OP
amplitudes by 54.5%. The effect of age on genotype was also examined for all measured
variables (data not shown, Appendix B, Table B.6A) Sample size per cohort can be found
in Figure 2.1B. Asterisks indicate statistical significance (* p < 0.05, ** p < 0.005) and
error bars represent ± 1 standard error of the mean.
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Figure 3.3.10hqY mice have changes in OP waveform frequency as early as two
months of age, followed by subsequent reductions of OP power and energy following
stimulus of 10 cd•s/m2. (A) Significant OP frequency reductions were evident
immediately at two months of age with a 14% decline in comparison to the wild type. OP
frequency continued to decline in hqY mice at 3 (26.6% reduction) and four months
(25.9% reduction) of age in comparison to the wild type. This was indicative of a
prolonged INL and GCL periodicity. (B) OP power is a measure of uniform retinal
response of the INL and GCL. OP power showed a significant reduction of 54.5% by five
to seven months in hq mice and continued to decline until eight to ten months. (C) OP
energy is the summation of total OP retinal energy and was not significantly different at
two or three months of age in hq mice. However, by four months of age hq mice show a
significant reduction of OP energy by nearly 28.3% which progresses to a nearly 52.3%
reduction by five to seven months of age. This indicates progressive disease in the hq
retina particularly in the INL and GCL response. The effect of age on genotype was also
examined for all measured variables (data not shown, Appendix B, Table B.6B) Sample
size per cohort can be found in Figure 2.1B. Asterisks indicate statistical significance
(* p < 0.05, ** p < 0.005) and error bars represent ± 1 standard error of the mean.
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(p = 0.029) is evident at four months of age resulting in a 28.3% reduction of OP energy
(Figure 3.3C). The decline in OP energy continues as the hq disease progresses and by
five to seven months an overall significant reduction (p = 0.0006) by 52.3% is apparent
(Figure 3.3C). No statistical conclusions can be made about OP frequency, power or total
energy at eight to ten months of age as the hq cohort only contains two mice, although
general trends appear to continue (Figure 3.3A, B,C).

3.4 Time-domain analysis of OPs indicate decreased summed amplitude in hq
carrier mice as early as eleven months of age following a 10 cd•s/m 2 stimulus
Initial latency of OP2 revealed no significant changes across all ages of the hqX
heterozygote when compared to the wild type (Figure 3.4A). Summed amplitude, a
measure of total inhibitory feedback mechanisms of the INL and GCL demonstrated no
significant changes at three months when compared to the wild type. In the elevenmonth cohort, a significant reduction of summed OP amplitude was evident (p = 0.011;
Figure 3.4B) at nearly 40.6%. Similarly, a significant reduction of 70.9% was observed in
summed OP amplitudes at fifteen months (p = 0.0341; Figure 3.4B) indicating overall
INL and GCL dysfunction and progression of the hq disease.
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Figure 3.4.11OP2-5 summed amplitudes indicates progressive loss of functional
feedback mechanisms of the hq carrier retina following a 10 cd•s/m2 stimulus. (A)
Initial latency of OP2 is indicative of the initial neural response between photoreceptors
and bipolar and horizontal cells of the INL and GCL. Although not statistically
significant at any age it is apparent that hqX may have a lengthened initial latency in
comparison to the wild type. (B) Summed amplitude of all OPs is indicative of the health
of the neural retina and the continuity of feedback mechanisms of the INL and GCL.
Significance is evident at eleven months of age with a 40.6% reduction in overall
summed amplitude. INL and GCL function continued to decline as demonstrated by a
significant reduction of OP summed amplitude by 70.9% at fifteen months. The effect of
age on genotype was examined for all measured variables (data not shown, Appendix B,
Table B.6C) Sample size per cohort can be found in Figure 2.1C. Asterisks indicate
statistical significance (* p < 0.05) and error bars represent ± 1 standard error of the
mean.
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3.5 OPs of hq carrier mice indicate early functional periodicity deficits and
subsequent reductions in retinal response continuity following a 10 cd•s/m 2
stimulus
OP frequency, a measure of response of periodicity and neural feedback
mechanisms across the INL and GCL, showed early functional deficits in hq carrier mice
at three months of age (p = 0.049) with an overall reduction of 10.9% (Figure 3.5A).
However, at eleven and fifteen months of age hq carrier mice showed no significant
difference in overall OP frequency (Figure 3.5A). Overall power, a measure of uniform
retinal response, showed no significant changes in hq carrier mice when compared to the
wild type at three months of age (Figure 3.5B). By eleven months of age, retinal
continuity in hqX mice is significantly reduced (p = 0.013) by 43.7% and progressive
decreases lead to a significant (p = 0.0047) 62.9% reduction by fifteen months (Figure
3.5B). OP total energy, a summation of total retinal response and analogous to OP
summed amplitude demonstrated no significant differences at both three and eleven
months of age in the hq carrier mice (Figure 3.5C). A significant difference was observed
in retinal OP total energy at fifteen months with a significant reduction (p = 0.002) of
66.3% (Figure 3.5C).

66

67
Figure 3.5.12Frequency-domain OPs expose early functional differences of
periodicity in three-month-old hq carrier mice and subsequent losses of OP power
and energy following a stimulus of 10 cd•s/m2. (A) Frequency of OPs is indicative of
periodicity of feedback inhibitory mechanisms of the INL and GCL. Significance in OP
frequency response changes in the hq carrier mice at three months, with the hqX mice
demonstrating a significantly lower OP frequency response. (B) OP Power is a measure
of uniform retinal response of the INL and GCL. Statistical significance is evident in hq
carrier mice at eleven months of age with an overall reduction of OP power by 43.7%.
OP power and INL and GCL function continued to decline in comparison to the wild type
leading to an overall reduction by 62.9% by fifteen months of age. (C) Energy of the OP
waveform is the summation of the total OP response and was not statistically significant
in three- and eleven- month-old hq carrier mice when compared to the wild type.
However by 15 months of age, OP energy was significantly reduced by 66.3% in hq
carrier mice indicting the progressive nature of the hq disease on INL and GCL function.
The effect of age on genotype was also examined for all measured variables (data not
shown, Appendix B, Table B.6D) Sample size per cohort can be found in Figure 2.1.
Asterisks indicate statistical significance (* p < 0.05, ** p < 0.005) and error bars
represent ± 1 standard error of the mean.
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3.6 NMDS of time-domain hqY OP parameters indicate functional differences in
OP latencies and amplitudes as early as two months of age
The stress associated with modelling all 32 time-domain variables from the severe
hqY disease progression study into a two-dimensional axis was 11.31%. Pearson’s
correlation coefficients were used for axis interpretation following NMDS of hqY OP
time-domain parameters (Appendix B, Table B.2). The x-axis (Coordinate 1) is highly
correlated to OPs with shorter latencies, particularly initial latencies of OP2 and OP3 at
all flash intensities (Figure 3.6). The x-axis is also positively correlated with increasing
OP amplitudes particularly amplitudes of OP4 and OP5 at all flash intensities. The y-axis
(Coordinate 2) is positively correlated to decreasing OP amplitudes across all flash
intensities (Figure 3.6). Young hqY and wild-type mice cluster distinctly at two months
of age with hqY mice demonstrating decreased OP amplitudes in comparison to the wild
type (Figure 3.6A). Aging of the hqY mice is associated with a sharp decline in OP
amplitudes and latencies between two and three months of age indicative of reduced INL
and GCL function (Figure 3.6A). The disease appears to be progressive, leading to
further reductions of OP latencies and amplitudes as the hqY mice age (Figure 3.6A).
Inter-animal variation is much higher in the hqY mice, likely due to variation in the
severity of retinal degeneration occurring in the hqY mice (Figure 3.6A). Wild-type mice
show little OP amplitude change and slight decreases in OP latencies through time
(Figure 3.6A).
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Figure 3.6.13hqY time-domain OP parameters indicate early (two months) losses of
INL and GCL periodicity and reduced retinal continuity at later ages. (A) Young
hqY mice cluster distinctly from young, wild-type mice at two months of age as a result
of reduced OP amplitudes and OP latencies. Progression of the hq disease leads to
continued loss of OP amplitude (particularly OP4 and OP5) and latencies across all other
age groups (months) resulting in severe losses of INL and GCL function. hq retina
degeneration shows great inter-animal variation. Young, wild-type mice at two months
demonstrate high OP amplitudes and short OP latency responses indicative of healthy
retinal responses and have marginal declines from ages two through seven months. By
eight to ten months, wild-type retinal function begins to decline with delayed OP latency
and decreasing OP amplitudes. (B) The average coordinates for each cohort were plotted
to assist with interpretation of NMDS clustering. Error bars represent ± 1 standard error
of the mean. Stress is equal to 11.31%.
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3.7 NMDS of frequency-domain OP parameters reveal distinct clustering of young
hqY mice associated with decreased OP power, energy and frequency
The stress associated with modelling all 12 frequency-domain variables from the
severe hqY disease progression study into a two-dimensional scale was 5.67%. Pearson’s
correlation coefficients were used for axis interpretation following NMDS of hqY OP
frequency-domain parameters (Appendix B, Table B.3). Coordinate 1 is highly correlated
with decreasing energy and frequency and slightly correlated with decreasing power at all
flash intensities (Figure 3.7). Coordinate 2 is highly correlated to decreasing power and
highly correlated to increasing OP frequencies at all flash intensities (Figure 3.7). Wildtype and hqY mice cluster distinctly at two months of age with hqY mice demonstrating
immediate lower total OP power, energy and frequency (Figure 3.7A). Distinctive hqY
clustering continues across all ages with progressive reductions of OP frequency, power
and energy (Figure 3.7A). Inter-animal variation is much higher in the hqY mice, likely
due to variation in the severity of retinal degeneration occurring in the hqY mice (Figure
3.7A). Young, wild-type mice cluster with high OP energy, power and frequency and
with only marginal reductions in any parameter with age (Figure 3.7A).
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Figure 3.7.14hqY frequency-domain OP parameters reveal distinct loss of overall
retinal periodicity and continuity of the INL and GCL response as early as two
months. (A) Young hqY and wild-type mice cluster distinctly demonstrating an
immediate reduction in overall OP frequency, power and total energy and loss of retinal
function. Aging of hqY mice (three-ten months) leads to progressive loss of all
frequency-domain OP parameters. Severe losses in OP energy and frequency are most
prominent between two and three months of age in hqY mice. Young, wild-type mice
(two months) cluster with high OP frequency, power and total energy and have slight age
related decreases (three to ten months). Progression of aging in wild-type mice shifts
NMDS parameters similar to that of young hqY mice (two months). (B) The average
coordinates for each cohort were plotted to assist with interpretation of NMDS clustering.
Old wild-type mice cluster similarly with young hq disease mice. Error bars represent ±
1 standard error of the mean. Stress is equal to 5.67%.
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3.8 NMDS of hq heterozygote time-domain parameters expose distinct clustering at
eleven and fifteen months of age
The stress associated with modelling all 32 time-domain variables from the
moderate hqX disease progression study into a two-dimensional scale was 9.84%.
Pearson’s correlation coefficients were used for axis interpretation following NMDS
(Appendix B, Table B.4). The x-axis (Coordinate 1) is highly correlated to short OP
latencies, particularly of OP2 and OP3 as well as high OP3 and OP4 amplitudes (Figure
3.8). The y-axis (Coordinate 2) is highly correlated to decreasing OP amplitudes across
all flash intensities (Figure 3.8). Young hq carrier and wild-type mice (three months)
cluster together with long OP latencies and intermediate amplitudes (Figure 3.8A).
However by eleven months, hq mice shift towards decreased OP amplitudes and shorter
latencies indicative of enhanced periodicity but loss of continuity of neural feedback
response. By fifteen months of age hq carrier mice demonstrate a large delay in OP
latencies with small OP amplitudes resulting in overall decreased retinal function (Figure
3.8A). Aging of wild-type mice (eleven and fifteen months) is associated with marginal
decreases in OP amplitudes and enhanced OP latencies (Figure 3.8A).

3.9 NMDS of frequency-domain hq carrier mice OP parameters demonstrate
progressive loss of OP power and energy at eleven and fifteen months
The stress associated with modelling all 12 frequency-domain variables from the
moderate hqX disease progression study into a two-dimensional scale was 3.84%.
Pearson’s correlation coefficients were used for axis interpretation following NMDS of
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Figure 3.8.15hq carrier time-domain OP parameters demonstrates distinct
clustering at 11 and fifteen months associated reduced initial INL/GCL response
and decreased continuity of overall retinal response. (A) Young hq carrier and wildtype mice cluster similarly with reduced OP initial latency and intermediate amplitudes at
three months of age. This is indicative of reduced photoreceptor and INL and GCL
periodicity and continuity of INL and GCL function at a young age. By eleven months of
age, hq carrier mice demonstrate distinct clustering associated with delayed initial OP
latency and a reduction in OP amplitudes when compared to age-matched wild type. As
the hq disease progresses, further reductions are evident in both OP initial latency and
amplitudes at fifteen months and as a result of incomplete retinal function. Aging of wildtype mice is associated with marginal decreases in OP amplitude and increases in OP
latencies and ultimately little change in retinal function. (B) The average coordinates of
each age cohort were plotted to assist with interpretation of NMDS clustering. Error bars
represent ± 1 standard error of the mean. Stress is equal to 9.84%.
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Figure 3.9.16Frequency-domain OP parameters of hq carrier mice indicates distinct
clustering associated with INL and GCL dysfunction at eleven and fifteen months.
(A) Young (three months) hqX and wild-type mice cluster similarly based upon high OP
power and energy and low frequency. hq disease progression at eleven months is
indicative of large reductions in total OP power and energy as well as increased OP
frequency. Further reductions of OP power and energy are evident at fifteen months with
additional reduced OP frequency. Aging of wild-type mice is associated with increases in
OP frequencies and minimal reductions in overall OP total power and energy. (B) The
average coordinates for each cohort were plotted to assist with interpretation of NMDS
clustering. Error bars represent ± 1 standard error of the mean. Stress is equal to 3.84%.
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hqX OP frequency-domain parameters (Appendix B, Table B.5). The x-axis (Coordinate
1) is highly negatively correlated to both OP total energy and power across all flashes
while the y-axis (Coordinate 2) is highly positively correlated to frequency across all
flashes (Figure 3.9). hq carrier and wild-type mice cluster similarly at three months of
age with hqX mice demonstrating slightly lower OP frequency, power and energy (Figure
3.9A). By eleven months of age, hq carrier mice cluster distinctly with higher OP
frequency and significantly reduced OP power and energy (Figure 3.9A). This general
trend progresses as hq carrier mice progress to older ages with further reductions in OP
power and energy indicative of reduced continuity of INL and GCL retinal response
(Figure 3.9A). Aging of wild-type mice is associated with increases in OP frequency and
marginal decreases in OP power and energy (Figure 3.9A).

3.10 hq mice maintain blood retinal barrier integrity at both a young and old age
To estimate concentrations of the Evans Blue (EB) dye in tissue, a standard curve
was created through a series of dilutions of EB in formamide. EB dye dissolved in
formamide maintain a linear relationship between 250 to 10000 ng/mL (Figure 3.10A, r2
= 0.999, y = 7.87 x10-6x + 0.002). The liver is a region of full vascularization and
therefore no blood endothelial barrier is present. To infer sensitivity of the assay a series
of tests were performed as described below. Significantly more EB was found in the liver
of EB injected wild-type mice than in uninjected controls (n = 4 per cohort, One-way
ANOVA, p < 0.001). No significant difference in EB amount was found in the retina of
wild-type mice injected with EB and uninjected wild-type mice (n = 4 per cohort, Oneway ANOVA, p > 0.05) indicating an intact BRB in wild-type mice. In addition, wild-
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type mice show significantly more EB in liver than retina at both a young and old age
(Figure 3.10 B, n = 4 per cohort, Two-way ANOVA, p < 0.005) but no significant
reduction with age (Figure 3.10B, n=4 per cohort, Two-way ANVOA, p > 0.05). hq mice
show a similar trend with significantly more EB in the liver than retina at both ages
(Figure 3.10 C, Two-way ANOVA, p < 0.005) but no significant reduction with age
(Figure 3.10C, Two-way ANOVA, p > 0.05). In order to account for technical variation,
retina EB amount was normalized to liver EB amount and no significant difference in
retina/liver ratio was found across all cohorts indicating a similar amount of EB is present
in the retina across all cohorts. This evidence suggests that there is no degradation of the
BRB in hq mice (Figure 3.10, Two-way ANOVA, p > 0.05).

3.11 Pathway analysis reveals differential expression of focal adhesion,
extracellular remodeling, cell stress and inflammation in the four-month hq retina
Four-month-old hq retinal gene expression microarray data (n=3 per cohort)
previously performed by A. Laliberté (2010),103 was filtered using selection criteria set at
a 1.75 fold change (mRNA transcript level) and a p-value less than 0.05. This revealed a
total of 521 genes that were differentially expressed between retinal tissue from hqY
mice and age-matched wild-type mice. A total of 182 genes were downregulated by
greater than 1.75 fold, and a total of 339 were upregulated by greater than 1.75 fold.
KEGG pathway analysis revealed pathways with significant proportions of differentially
expressed genes. Significant pathways involved in extracellular remodelling, ABC
transport, immune response, inflammation, cell cycle and p53 signalling were
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Figure 3.10.17hqY mice maintain a blood-retinal-barrier similar to that of agematched wild-type mice. (A) Evans Blue standards in formamide maintain a linear
relationship between concentration and background-subtracted absorbance (r2 = 0.999, y
= 7.87 x10-6x + 0.002). Standards were tested by three different people in triplicate and
were virtually identical. (B) A significantly higher concentration of Evans Blue dye is
present in the liver in comparison to retina in wild-type mice at both ages. (C) Similarly,
a significantly higher concentration of Evans Blue dye is present in the liver of hqY mice
in comparison to retina across both ages. (D) Liver-normalized retinal Evans Blue
amount is not significantly different across any cohort indicating an intact blood-retinal
barrier.
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differentially expressed in the hq retina (p < 0.01) (Table 3.1). Additional DNA repair
and cancer pathways were also differentially expressed (p < 0.05) (Table 3.1).

KEGG pathway analysis allowed for a comprehensive overview of differential
expression in the hq mouse retina. However, due to the nature of KEGG gene annotations
(not retinal specific) and containing only single genetic isoforms, only 177 gene IDs out
of the 521 were represented the software analysis. Therefore, well over 65% of genes
differentially expressed in the expression microarray were not used by KEGG pathway
software. To account for this bias, a manual annotation of all differentially expressed
genes was performed (Appendix E). A thorough review yielded an alternative
metabolism theme, common amongst AIF knock-downs including; the upregulation of
glucose metabolism, lactate acidosis, and glycerol metabolism. Genes present in these
pathways were selected for Taqman® qPCR analysis (Table 3.2).

3.12 Cerebellar and retinal RNA quality was assessed prior to transcriptional
analysis
Spectrophotometry, gel electrophoresis and Bioanalyzer spectra all indicated the
presence of high quality cerebellar RNA. Cerebellar samples were only chosen if they
indicated a concentration greater than 140 ng/uL and a high absorbance ratio (A260/A280
> 1.8) (Appendix B, Table B.7). Gel electrophoresis allowed quantification of the 28S
and 18S ribosomal RNA (rRNA) subunits as well as the potential for gDNA
contamination. Samples were only selected if they demonstrated distinct rRNA subunits
with no gDNA contamination (Figure 3.12). Samples were also analyzed via Bioanalyzer
spectra and selected if there was clear separation of 28S and 18S peaks (Figure 3.13A)
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Table 3.1. KEGG pathway analysis based on microarray data of differentially
expressed genes from retinal samples of four-month-old hq disease mice.*,†
Pathway

p-value‡

Number of
Differentially
Expressed Genes

Gene Enrichment
Percentage (%)

ECM-receptor
interaction

6.9 x 10-6

13

2.5

ABC transporters

5.5 x 10-5

9

1.8

Focal Adhesion

1.0 x 10-4

18

3.5

Viral myocarditis

5.5 x 10-4

11

2.1

p53 signaling pathway

4.9 x 10-3

8

1.6

Cell cycle

5.7 x 10-3

11

2.1

Complement and
coagulation cascades

7.8 x 10-3

8

1.6

Tight junction

8.2 x 10-3

11

2.1

Regulation of actin
cytoskeleton

0.015

14

2.7

Pathways in cancer

0.02

18

3.5

Small cell lung cancer

0.046

7

1.4

* Microarray was performed by A. Laliberté (2010). 103
†

Pathway analysis was performed with the Database for Annotation, Visualization, and

Integrated Discovery (DAVID) [National Cancer Institute at Frederick, Frederick,
MD].141,142
‡ Pathway is ordered by increasing p-value.
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Table 3.2. Genes of interest from four-month-old hq mice selected from retinal
microarray data for Taqman® validation.
Function†

Symbol

Adenylate cyclase
10

Adcy10

Key intracellular regulation of pH
and bicarbonate buffering

0.005

+2.858

Glycerol-3phosphate
dehydrogenase 2

Gpd2

Secondary step of glycerol
metabolism, feeds into glycolysis

0.04

+2.377

Aldehyde
dehydrogenase 2

Aldh2

Primary step for conversion of
Acetyl-CoA to acetate

0.045

+2.345

Glycerol Kinase 5

Gk5

Primary step of glycerol metabolism,
feeds into glycolysis

0.048

+1.998

TBC1 domain
family, member 4

Tbc1d4

Responsible for shuttling Glut4 to the
plasma membrane from the
endoplasmic reticulum

0.03

+1.992

Hexokinase 1

Hk1

Initial step of glycolysis in the retina
– drives glycolytic rate

0.037

+1.964

Glucose
transporter,
member 4‡

Glut4

Rapid, insulin dependent glucose
transporter responsible for glucose
intake in neurons

0.023

+1.4

Lactate
dehydrogenase C‡

Ldhc

Responsible for reverse reaction of
L-lactate to pyruvate

0.018

-1.63

Pyruvate
dehydrogenase,
component X

Pdhx

Structural component of pyruvate
dehydrogenase complex

0.016

-2.482

Sodium
bicarbonate
transporter,
member 10

Slc4a10

Bicarbonate transporter to remove
excess CO2 from mitochondria

0.027

-2.873

Apoptosisinducing factor 1

Aif

Complex I efficiency and
maintenance, apoptosis inducer.

0.0002

-6.012

†

p-value

Fold

Gene Name

Change

Functional annotation was based on NCBI, GENE search annotation [National Institute

of Health, Bethesda, MD]
‡

Previous literature suggests increased glucose metabolism and lactate acidosis in hq

mice, therefore Glut4 and Ldhc (p < 0.05, < 1.75 fold change) were added for
examination.
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Figure 3.11.18Agarose gel electrophoresis demonstrates high quality cerebellar
RNA samples with distinct 28S and 18S ribosomal subunits. A representative gel of
11 samples indicates the presence of high quality cerebellar RNA (distinct 28S and 18S
bands) electrophoresed with a 1 kb+ DNA ladder [Life Technologies, Burlington, ON].
Sample 925.45 (lane 5) presented contamination with high molecular weight gDNA. A
negative control of water was electrophoresed in the final lane (lane 13).
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Figure 3.12.19Electropherograms indicate high RNA quality of both cerebellar and
retinal samples. (A) A representative electropherogram of intact, high quality cerebellar
RNA using the Agilent 2100 Bioanalyzer [Agilent Technologies Inc., Palo Alto, CA].
RNA quality is a measure of fluorescence (FU) and nucleotide (nt) size. An initial
fluorescence peak at 25 nt represents a size marker, followed by a clear distinction of the
18S (~1500 nt) and 28S rRNA subunits (~4000 nt). A representative agarose gel image is
created (right hand side) based on fluorescence of rRNA peaks. (B) A representative
electropherogram of intact, high quality retinal RNA. Fluorescence is much lower due to
a lower concentration, however a clear separation of the 18S and 28S rRNA subunits is
still evident. (C) A retinal RNA electropherogram with gDNA contamination. Sheared
gDNA and degradation products show similar properties to the 28S rRNA subunit and
lead to skewing of the rRNA peak.
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as well as an RNA integrity number (RIN) greater than 8. Retinal samples were subject
to the same spectrophotometric (concentration > 16 ng/uL) and Bioanalyzer assessment
(Figure 3.13B) (Appendix B, Table B.7). Gel electrophoresis was not performed with
retinal samples as the RNA concentrations were too low. All retinal RNA samples used
for transcriptome analysis were of high quality.

3.13 Taqman® quantitative PCR confirms metabolic and cell regulation changes in
the hq mice retina and cerebellum
Aif was significantly downregulated (p < 0.001, fold change < 11.312) in the hq
retina at four months, three months, and two months (Table 3.3) of age as well as
significantly (p < 0.001, fold change = -8.8183) downregulated in the four-month hq
cerebellum (Table 3.4). Cyclin-dependent kinase inhibitor 1A (Cdkn1a), responsible for
inhibiting cell cycle, was significantly (p < 0.05) upregulated in the hq retina at four
months, three months and two months of age (Table 3.3) as well as the four-month
cerebellum (Table 3.4). Genes associated with metabolism were upregulated in the fourmonth hq retina (Table 3.3) including; Adcy10 (p = 0.0013, fold change = +1.7995),
Slc4a10 (p = 0.0024, fold change = 1.8102), Gk5 (p = 0.0021, fold change = +1.7995),
Aldh2 (p = 0.017, fold change = +1.660), Gpd2 (p = 0.023, fold change = +1.274) and
Pdhx (p = 0.027, fold change = +1.250).

No genes involved in metabolism were

differentially regulated in the three-month hq retina (Table 3.3). However, Gk5 (p =
0.022, fold change = +1.2688) and Aldh2 (p = 0.0465, fold change = +1.289) were found
to be differentially expressed early in the two- month hq retina (Table 3.3).

One

metabolism gene was found to be differentially expressed in the four-month hq
cerebellum (Table 3.4); Adcy10 (p = 0.0265, fold change = +2.2422).

90
Table 3.3. Differential gene expression of selected genes in the hq retina at two, three
and four months of age based on Taqman® RT-PCR.*

Gene

Two months

Three months

Four months

Name

Fold change‡

Fold change‡

Fold change‡

(p-value†)

(p-value†)

(p-value†)

Aifm1

- 12.315 (<0.001)

- 17.301 (<0.001)

- 11.312 (<0.001)

Adcy10

+ 1.7285 (0.0878)

+ 1.5042 (0.6607)

+ 1.7995 (0.0013)

Gk5

+ 1.2688 (0.0219)

+ 1.0664 (0.60)

+ 1.8102 (0.0021)

Slc4a10

+ 1.1164 (0.1655)

+ 1.0728 (0.4052)

+ 1.4990 (0.0024)

Cdkn1a

+ 2.2391 (0.0334)

+ 1.6654 (0.0053)

+ 3.2214 (0.0063)

Aldh2

+ 1.2889 (0.0465)

- 1.0963 (0.5967)

+ 1.660 (0.017)

Gpd2

+ 1.2586 (0.1036)

- 1.106 (0.6446)

+ 1.274 (0.023)

Pdhx

+1.1222 (0.1319)

+1.0285 (0.6297)

+1.250 (0.027)

Hk1

+ 1.1442 (0.1780)

- 1.007 (0.997)

+ 1.286 (0.060)

Rn18s

+ 1.4432 (0.3058)

+ 1.0531(0.7299)

+ 1.361 (0.270)

Tbc1d4

+ 1.2331 (0.2442)

n/a

+ 1.091 (0.344)

Glut4

+ 3.2467 (0.1107)

- 2.8596 (0.3161)

- 2.898 (0.832)

Ldhc
n/a
n/a
n/a
* Gene order was established by ascending four month p-value, bold genes indicate
significance.
† An ANOVA was used in Excel [Microsoft, Redmond, VA] to determine significance of
the ΔCt values.
‡ Fold change was determined with DataAssistTM software [Life Technologies,
Burlington, ON] using the comparative Ct (ΔΔCt) method.140
n/a - indicates late amplification.
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Table 3.4. Differential gene expression of selected genes in the hq cerebellum at four
months of age based on Taqman® RT-PCR.*
Gene Name

p-Value†

Fold Change‡

Aifm1

<0.001

- 8.8183

Cdkn1a

0.0251

+ 1.6291

Adcy10

0.0265

+ 2.2422

Slc4a10

0.1409

+ 1.4275

Tbc1d4

0.1409

+ 1.2278

Glut4

0.1624

+ 1.6189

Gk5

0.1792

+ 1.4212

Pdhx

0.2217

+ 1.1763

Rn18s

0.2776

+ 1.3111

Hk1

0.4030

+ 1.1589

Gpd2

0.4065

+ 1.1127

Aldh2

0.4159

+ 1.1105

Ldhc
n/a
n/a
* Gene order was established on ascending p-value, bolded genes indicate significance.
† An ANOVA was used in Excel [Microsoft, Redmond, VA] to determine significance of
the ΔCt values.
‡ Fold change was determined with DataAssistTM software [Life Technologies,
Burlington, ON] using the comparative Ct (ΔΔCt) method.140
n/a - indicates late amplification.
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3.14 hqY mice have a decreased total body mass but display hyperphagia at four
months
The mean body mass of hqY diseased mice at four months (22.422 ± 0.9993g) was
significantly lower (p < 0.001) than age-matched wild-type mice (29.512 ± 0.5362g)
(Figure 3.13A) with a 24% reduction in total body mass. Although hqY mice exhibit
smaller mean body mass, they display hyperphagia at four months with a significant
increase (p < 0.001) in mean food consumption (0.1991 ± 0.01 grams of food/gram of
body mass/day) in comparison to the wild type. This overall increase is nearly 34.4%
(0.1481 ± 0.002 grams of food/gram of body mass/day) in hqY mice (Figure 3.13B).
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Figure 3.13.20Feeding study indicates hyperphagia in hq mice at four months of age.
(A) hq mice demonstrate a significantly lower mean body mass in comparison to agematched wild-type mice. (B) Mean daily food consumption was significantly higher in hq
disease mice indicating hyperphagia. Sample size was four per cohort, asterisks indicate
significance (*p < 0.001) and error bars represent ± 1 standard error of the mean.
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Chapter 4. Discussion
4.1 Early hq retinal dysfunction can be tracked to the inner retina through the
study of oscillatory potentials
Previously, it was shown that OXPHOS dysfunction in the hq retina is associated
with parainflammatory disease as early as 1.8 months of age, resulting in microglial
migration to the ONL and subsequent ONL cells losses.103,104 To date, early mechanisms
prompting retinal degeneration in the hq mouse have yet to be elucidated. It was
predicted that oscillatory potentials could be used to track hq disease progression because
of their association with hq hallmarks of the retinal disease including degeneration of the
ONL, IPL, OPL as well as ganglion and amacrine cells. Herein, at the retinal
physiological level, in vivo diagnosis of electrophysiological response in the hq retina
was able to identify early, diagnostic candidates of retinal malfunction including OP
frequency and initial latency. NMDS provided a thorough visualization of OP waveforms
across multiple flash intensities and identified changes across all measured parameters of
OP profiles.
Due to the highly metabolic nature (continuous transport) of the BRB, it was
unknown whether the severe neurodegeneration in the hq retina was the result of BRB
degradation or endogenous retinal stress caused by reduced AIF function. Loss of BRB
integrity leading to exogenous antigens larger than the Evans Blue albumin complex
traversing the BRB was rejected as a proposed mechanism for chronic microglial
activation in the hq retina. Thus, triggers of chronic microglial activation are
hypothesized to be the result of an endogenous cellular stress mechanism. Early
transcriptome changes in the hq retina are consistent with partial compensating metabolic
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mechanisms in an attempt to maintain production of ATP in vivo. Such as, glycerol
metabolism to generate FADH2 which enters OXPHOS distal to NADH dehydrogenase.
This study provides the first, in vivo, preliminary evidence for alternative metabolism in
the retina of the hq mouse and is the basis for subsequent future examinations of hq
retinal metabolism.

4.2 Oscillatory potentials are relevant for the study of hq retinal degeneration
Oscillatory potentials (OPs) are the intermediate peaks on the ascending limb of the
ERG b-wave. OPs are believed to correspond to inner retinal function of the ON-, OFFand feedback mechanisms of the INL and GCL. OP subgroups, beginning with
intermediate OPs represent the proximal action-potential independent (bipolar and
horizontal cell graded potentials) and action-potential dependent mechanisms of ganglion
cells and amacrine cells of the inner retina (Figure 4.1).56 Additionally, the interplexiform
cell which spans the OPL and IPL may generate radial current flow (feedback) from
lateral synapses of the OPL and IPL and may be responsible for oscillations. 54,55 This is
particularly beneficial for the study of hq retinal degeneration. Neurites of the OPL and
IPL contain the synapse between dendrites and axons of adjacent neurons relaying
electrochemical signal from the OS. They are the most energetic region of the neurons
and hence hq mice exhibit considerable thinning of the neurites93 as well as upregulation
of neurite remodelling and maintenance genes.103 These genes include; Sodium channel
beta 4 subunit (Scn4b), and Sterile alpha motif domain containing 4 (Samd4) both of
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Figure 4.1.21Isolated oscillatory potentials (OP1-OP5) may correspond to retinal
layer functionality. OP1 is associated with photoreceptor hyperpolarization (red).
Intermediate peaks OP2-OP3 are believed to be the response of second-order horizontal
(blue) and bipolar (purple) action-potential independent (graded) neurons. Subsequent
late OP peaks are believed to be associated with action-potential dependent amacrine
(green) and ganglion (orange) cells. Intermediate OP peaks are thereby generally
associated with INL function and later OP peaks with GCL function. Radial
electrochemical cycling is the result of feedback mechanism occurring across the IPL of
the retina.
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which are involved in maintenance of neurite function and synaptic health.103 In addition
to neurite loss, the first histological hallmarks of retinal degeneration begin at three
months of age, with retinal thinning of the ganglion and amacrine cells.93 Oscillatory
potentials measure retinal health and signal transduction through the retina and can
therefore assess the health of both the neurites and the ganglion cells prior to structural
losses. OPs are capable of detecting early changes as a result of mitochondrial
dysfunction prior to any functional losses in the hq retina as diagnosed by the ERG awave and b-wave.

4.3 The hqY mouse shows early neuronal functional deficits
In the longitudinal study of ERG OPs through the hq disease, OP profiles changed
in both the time and frequency domain. The initial latency of OPs indicated that
functional changes began as early as three months of age in hq mice. Simultaneously,
changes in the major frequency of the OPs began at two months of age in the hq mouse
and were followed by a steep reduction in OP frequency occurring between two and three
months of age. Major frequency and initial latency are informative of periodicity and
likely a response of radial current cycling through the inner retina and therefore are
indicative of the speed of the graded potential changes in the INL and GCL as a result of
photoreceptor synapsis leading to depolarization of the bipolar cells. Analysis in the
frequency domain is advantageous when examining periodicity of OPs because it
identifies significant changes across hq retina function prior to the time domain.
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Significant decreases in OP summed amplitude began at four months of age in the
hq mouse and continued into later ages with diminished total OP amplitude. Analogous
changes in the frequency domain demonstrate decreases in total OP energy occurring at
four months of age. Both the summed amplitude and total energy are indicative of total
energetic response of the OPs, and therefore the functionality and health of all cells in the
inner retina. Decreases of both hq OP summed amplitude and total energy are likely due
to neuronal cell loss of the ONL, INL and GCL as decreasing OP amplitudes have been
implicated in structural retinal loss.56 Summed OP amplitude can therefore be used as a
measure of overall inner retinal health as previously described in other models.66,78,79
In the hq mouse, inner retinal functional deficits as a result of changes in OP
frequency and latency occur prior to any documented structural losses at four
months.19,93,102 These functional differences occur as early as two months of age and are
consistent with a neuronal synaptic malfunction and microglial activation at
complementing ages in the hq retina. The activation of microglial cells and OP functional
deficits of the inner retina coincide at two months and indicate the loss of homeostasis
and neuronal synaptic malfunction.

4.4 The hqX mouse demonstrates slower disease progression of the inner retina
The hq carrier mouse phenotype displays a moderate, extended disease phenotype
in comparison to the hemizygous or homozygous disease mice.93,102,103 The functionality
of the inner retina, as measured by OPs of the ERG, demonstrate consistent moderate
phenotypic results. In fact, no OP initial latency or frequency changes were observed in
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the hq carrier mice at any age. This is indicative of no periodicity change in the retina of
the hq carrier mice and sufficient responses of the synapsis between ONL: INL and
INL:GCL neurons and overall vitality of the ONL photoreceptors. However, decreases in
both amplitude and analogous energy and power indicate inner retinal cell losses and
decreases in INL and GCL function at eleven months of age. Retinal thinning in the hq
carrier retina is not evident until approximately fifteen months when structural losses of
the INL and ONL occur.103 Therefore OPs identify physiological changes of the INL
(bipolar and amacrine cells) prior to any structural cell loss and reveal a diagnostic
parameter to assess retinal health before cell death has occurred.

4.5 hqY OP functional losses mimic retinopathy and may help reveal the origin of
OPs
Mammalian retinopathy begins with photoreceptor loss in the ONL. Retinopathy
leads to hyperoxia in the inner retina caused by oxidative challenges, neovascularization,
and inflammation.143,144 Recent studies, of both human and rat scotopic ERGs have
demonstrated the functional disease progression of retinopathy and its effect on OPs.
Retinopathy leads to decreases in all OP amplitudes, particularly that of early OPs,
indicative of persistent dysfunction of photoreceptors.66,78 Deterioration of OP amplitudes
and total OP energy in hq disease mice indicates similar disease mechanisms to that of
retinopathy as health of photoreceptors is diminished.
Aging has been associated with nuclear losses in the INL and GCL leading to
compromised retinal function with senescence.66,145,146 Aging leads to the progressive
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loss in OP periodicity (initial latency and frequency) in wild-type rats and humans,66,146
analogous to periodicity changes in the hq retina. The deficits in hq OPs demonstrate
persistent effects of hypomorphic AIF on retinal function leading to mitochondrial
dysfunction, photoreceptor cell death, retinal degeneration and an advanced aging
phenotype. A thorough histological characterization of hq retina neuron losses indicates
OP are generated in the INL and GCL and are helpful in the investigation of the source of
OP production in the retina.102,132

4.6 Non-metric multidimensional scaling offers a comprehensive visualization of
inner retinal function with genotype and age
The measurement of each OP amplitude and latency in the time domain provided a
total of eight measurements for each flash intensity (excluding OP1 due to
inconsistencies and photoreceptor contamination). Four flash intensities (0.63, 4, 10 and
25 cd •s/m2) were examined as they all contained strong and measureable OP responses.
Across the four flash intensities 32 measurements were taken in the time domain and 12
measurements in the frequency domain for each mouse.
NMDS computationally-derived coordinates fitted to 32 time-domain variables into
two dimensions and 12 frequency-domain variables into two dimensions. The stress
associated with modelling multiple parameters into two dimensions was low across all
four analyses and demonstrates a valid, comprehensive evaluation of OPs across multiple
stimulus intensities. NMDS analysis provided a valuable interpretable aid in examining
disease progression and provides translational relevance in determining origins of disease
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and potentially identifying drug targets. Pearson’s correlation coefficients were used to
examine the correlation of each axis with each of the fitted variables to determine which
variables participate most into axis determination. For example, flash eight OP2
amplitude may be highly positively correlated with the x-axis and therefore any sample
with high flash eight OP2 amplitude will receive a high ordination on the x-axis. NMDS
of OP parameters both in the time domain and frequency domain provided a visual aid in
examination of disease progress as well as an interpretation of OP parameters and their
impact on disease.

4.7 NMDS of hqY mice reveals distinct functional retinal changes by two months
of age
NMDS of time-domain OP parameters reveals that young, hqY mice (two months
of age) cluster distinctly from wild-type mice and demonstrate early characteristics of
retinal dysfunction. Through axis interpretation with Pearson’s correlation coefficients it
is evident that young, hqY mice (two months of age) cluster in regions of low, early OP
amplitudes (OP2-OP3) as well as decreasing initial latencies across all flash intensities.
Age-matched wild-type mice cluster in regions of high, late OP amplitudes (OP4-OP5) at
all flash intensities as well as short initial latencies across all flash intensities. It is
therefore apparent that mechanisms of the hq disease lead to early OP latency increases
and amplitude loss followed by both latency increases and amplitude reductions across all
OPs later in life. This is consistent with previous findings indicating that hq mice
experience ONL losses at four months of age.19,93 However, this evidence suggests that
functional changes may occur as early as two months in the hq photoreceptors and INL
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cells. An interesting observation is that ten-month-old wild-type mice cluster similarly to
that of two-month-old hq mice indicating that young hq mice show retinal functional
losses similar to that of middle-age wild-type mice. Ageing has been shown to affect rod
photoreceptor function leading to a 40% reduction in mouse rods.147 This suggests that hq
mice exhibit ERG features similar to an advanced aging phenotype leading to
photoreceptor losses and decreased INL and GCL function.
In the frequency domain, young two-month-old hqY mice cluster distinctly with
reductions in power and frequency in comparison to wild-type mice across all flash
intensities. Wild-type mice cluster in regions of high energy, power and frequency across
all ages with minimal OP changes with age. Aging of the hq mouse demonstrates
dramatic reductions in OP frequency, power and energy, particularly between two and
three months of age. This is indicative of reduced radial current feedback in the hq retina
due to reductions in periodicity and overall INL and GCL function resulting in reduced
neural retina response and OP generation.

4.8 NMDS of hqX mice reveals distinct retinal changes at eleven months of age
NMDS of time-domain parameters indicates that middle-aged (eleven months of
age) hqX mice cluster distinctly with reductions in both early and later OP amplitudes
(OP2-OP5) as well as shorter overall latencies. Age-matched wild-type mice indicate
slight reductions in all OP amplitudes but shortened overall latencies across all flash
intensities. These functional decreases would indicate that the hqX mice lose the
functionality of the overall retinal response and likely experience neurite losses in both
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the OPL and IPL. Cell loss and subsequent retinal thinning does not occur in the INL and
GCL until fifteen months of age in the hqX mice,103 however functional changes are
evident early through NMDS of time-domain OPs.
In the frequency domain, middle-aged hqX mice (eleven months of age) cluster
distinctly with large overall reductions in OP power and energy across all flash intensities
and increases in OP frequency with age. Wild-type mice of similar ages cluster in regions
of sustained OP power and energy with increased frequency. Functional losses in total
OP energy and power indicate a delayed and stunted response of the radial current
feedback of the INL and GCL. This is prior to any structural losses and indicates an early
functional diagnosis of the hqX retinal disease.

4.9 The hq mouse retina maintains an intact inner and outer blood-retinal barrier
Assessments of the blood-retinal barrier via Evans Blue circulation indicate no
increase in EB concentrations in the retina of hq mice when compared to age-matched
wild-type mice. Although endothelial cells of the inner and epithelial cells of the outer
retina (RPE) blood barrier are highly metabolic, they retain functional tight junctions
with limited diffusion of exogenous EB from the vasculature into the sensitive inner
retinal space. This is consistent with the alternate hypothesis of activation of hq retinal
microglial cells from an endogenous source due to diminished AIF function leading to
cell stress and loss of retinal neurons. Although retinal endothelial and epithelial
vasculature are rich in mitochondria and highly metabolic, a probable explanation of
integrity is due to maintenance by glia.148 Glial cells rely heavily on glycolytic ATP as
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well as lactate and therefore a deficiency in OXPHOS will not compromise glial
function.119 Glial cells have been shown to enhance blood-retinal barrier properties by
increasing tight junction protein expression, endothelial-1,149 as well as

providing

neuronal support150 for both the outer151 and inner33 retina. It would be expected that a
reduction in complex I functionality and ATP production accompanying hq mice leads to
a blood-retinal barrier malfunction but continued support from aerobic glial cells
promotes the continued formation of tight junctions and maintenance of the blood-retinal
barrier.

4.10 Transcriptome changes demonstrate Aif downregulation
Gene expression analysis of hq Aif is consistent with previous findings suggesting a
global downregulation of Aif mRNA transcript by over 80%.93 Contrary to previous
findings downregulation of Aif in the retina surpasses an 80% reduction in the retina of
four-, three-, and two-month-old mice to a downregulation by 91.16%, 94.22% and
91.88% respectively. This finding is consistent with quantified protein expression in the
hq retina indicating minimal to nil endogenous AIF expression and complex I efficiency
in the hq retina.95,98 Regulation of hq Aif gene expression occurs prior to transcription and
specifies that the regulatory region of intron 1 is more vital in the retina than other
tissues. The significant downregulation of Aif in the hq retina may explain the rapid onset
of retinal degeneration preceding other tissue malfunctions. Functional retinal deficits
begin at two months of age and an early reduction of Aif mRNA expression may be the
catalyst to early retinal degeneration in the hq mouse.
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4.11 The hq retinal transcriptome suggests alternative metabolism
As functional losses occur in the ONL of the hq retina, it is important to
characterize endogenous activation of microglial cells and changes that lead to cell loss.
The loss of Aif efficacy leads to reduced complex I function and expression resulting in
reduced ATP yield across a variety of tissues.95,98,118 As predicted, the hq retina at two-,
three- and four-months of age are unable to upregulate early, key enzymatic reactions of
the glycolytic cycle as demonstrated by Hexokinase I (Hk1). Hk1 catalyzes the first
regulatory, enzymatic reaction of glycolysis in the cytoplasm by phosphorylating glucose
to glucose 6-phosphate (Figure 4.2A).152 Overexpression of Hk1 drives high rates of
aerobic glycolysis, largely in cancers.153 Hk1 demonstrated no change in transcript levels
in the hq retina even after microarray data suggested it may be upregulated.
Previous studies suggest the role of increased glucose uptake in hq
mesodermal/endodermal tissues as a result of OXPHOS deficiency and a reliance on
glycolytic ATP.98,118 Glycolytic flux is believed to be primarily controlled at the level of
glucose uptake and phosphorylation of glucose by Hk1.154

In agreement with no

glycolytic changes in the hq retina, the expression of Glucose transporter 4 (Glut4), a
glucose transporter in the retina,155 demonstrates no significant changes in mRNA
expression. Glut4 is a rapid, time-scale glucose transporter that translocates to the plasma
membrane from the endoplasmic reticulum when insulin binds its receptors on the cell
surface (Figure 4.2A).156 This translocation is mediated by TBC1 Domain Family,
Member 4 (TBC1D4)157 which also showed no regulation changes in the hq retina at any
age. The regulation of Glut and Hk1 exhibit the high control over glycolytic flux154 and
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Figure 4.2.22Proposed mechanisms of altered metabolism in the hq mouse based on
significant alterations in the hq retinal transcriptome. Boxes coloured: blue indicate
enzymes, yellow indicate substrates/metabolites and green indicate reducing equivalents.
(A) Glucose metabolism in the hq retina, beginning with the uptake of glucose from the
extracellular space by GLUT4 and followed by regulatory steps of glycolysis (HK1,
PFKFP3) remain essentially unchanged. Metabolism of glycerol in the hq retina is
differentially upregulated beginning with the conversion of glycerol to glycerol 3phosphate by GK5. Mitochondrial bound GPD2 facilitates the conversion of glycerol 3phosphate to dihydroxyacetone phosphate by reducing FAD to FADH2. The glycerol
shuttle shuttles FADH2 into the mitochondria. In addition, the formation of
dihydroxyacetone phosphate from glycerol metabolism feeds into glycolysis and through
the formation of glyceraldehyde 3-phosphate (G3P). The dysfunction of complex I in the
hq retina causes an accumulation of NADH and decreased ATP production. (B) FADH2,
produced by the glycerol shuttle, can donate electrons distal to complex I and allow
improved functionality of OXPHOS in the hq retina.
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show no differential expression in the hq retina (Figure 4.2A). These observations
support no upregulation of transcript levels of glycolytic compensatory mechanisms for
neuronal ATP deficits cause by AIF dysfunction. This further confirms that neurons may
be unable to upregulate glycolysis as increased glycolytic rate leads to oxidative stress
and apoptotic cell death.45
Neuronal and glial cells do not preferentially metabolize triglyceride components
under healthy conditions.158 β-oxidation of fatty acids is not favoured in neurons because;
1) it requires high levels of oxygen thereby increasing risk of becoming hypoxic 2) it
leads to generation of superoxides and 3) has a slower ATP turnover in vivo.158 Glycerol
however, can traverse the blood-brain-barrier159 and be utilized as a neuronal
metabolite.160 A suspected similar mechanism may occur in the retina during periods of
ATP depletion and metabolic need. Glycerol metabolism is highly energetic as it fuels
ATP formation as well the ability to participate in the glycerol-3-phosphate (G3P) shuttle
by transferring reducing agents into the mitochondrion and leading to the formation of
FADH2 (Figure 4.2AB).160 The oxidative metabolism of glycerol leads to the formation
of one FADH2 reducing molecule before forming 3-carbon, dihydroxyacetone phosphate
which can enter the glycolytic pathway (Figure 4.2A). Glycerol-3-phosphate
dehydrogenase (Gpd2) and Glycerol kinase 5 (Gk5) encode the primary and
secondary enzymatic mediators leading to and facilitating glycerol metabolism in the
brain (Figure 4.2A).160 Both Gpd2 and Gk5 transcript levels were upregulated in the hq
retina at four months of age inferring neuronal metabolism of glycerol as a metabolic
means for ATP and FADH2 production. GK5 facilitates the primary step of glycerol
metabolism by phosphorylating glycerol to L-glycerol 3-phosphate and was upregulated
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at two-months of age and suggests a potential link between early hq disease and glycerol
metabolism.
Since OXPHOS of the hq mouse becomes dysfunctional, alternative mechanisms
for generation of ATP must occur in order for neurons of the retina to remain viable.
Excess glycerol fed into the later stages of glycolysis would lead to a bottleneck of
pyruvate oxidation (pyruvate dehydrogenase) and as expected the Pyruvate
dehydrogenase complex component X (Pdhx) of pyruvate dehydrogenase is upregulated
at four months. Pdhx is a structural component of the pyruvate dehydrogenase complex
that links the catalytic and regulatory subunits of the functional complex.161 Pyruvate
dehydrogenase complex is the metabolic link between glycolysis and the Tricarboxylic
(TCA) acid cycle by decarboxylating pyruvate to form acetyl-CoA (Figure 4.2A).
Deficiencies in Pdhx cause pyruvate dehydrogenase malfunction and have been
associated with neurological dysfunction and lactate acidosis.161 Although the
directionality of Pdhx expression based on Taqman® assay and microarray for Pdhx do
not agree, dysregulation infers an intracellular mechanism that may lead to lactate
acidosis in the hq retina and/or enhanced production of acetyl-CoA as a result of
increased glycerol metabolism. In vivo examination of PDHX activity may help resolve
its exact function in the hq retina.
OXPHOS complex I reduction in the hq mouse98 likely results in the inadequate
processing and utilization of reducing agents (NADH and FADH2) produced by the
mitochondrial TCA Cycle (Tricarboxylic Acid Cycle) (Figure 4.2). This is of particular
importance for NADH, which is primarily oxidized by the NADH dehydrogenase
complex (complex I) of the electron transport chain. A dysfunction of NADH
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dehydrogenase may disrupt the NAD+ pool, increasing the NADH/NAD+ ratio thereby
altering the redox state of the cell.162 In 80% of patients with complex I deficiency, high
levels of lactate/pyruvate were evident with severe increases in NADH/NAD+ ratios.163
Since it is likely that hq OXPHOS has compromised utilization of NADH, the
mitochondria may compensate by decreasing the throughput of the TCA Cycle (high
NADH concentrations decrease the activity of malate dehydrogenase, the primary step of
the TCA cycle164) and increase glycerol metabolism as a means to increase FADH2
production. FADH2 electrons enter the electron transport chain distal to complex I and
therefore can be used as an alternative electron source for driving the electron transport
chain in order to maintain its function.165
Severe increases in NADH/NAD+ are also associated with ketoacidosis and lactate
acidosis as a result of acetyl-CoA being converted into acetoacetic acid and betahydroxybutyric acid or lactate.166,167 Neuronal excitability is affected by intracellular
acid-base homeostasis,168 where a rise in pH is associated with increased neuronal
excitability, and a drop in pH reducing neuronal excitability.169,170 Acidic buffering to
maintain pH,

decreases intracellular concentration of HCO3- and further reduces

buffering capabilities of the cell.171 Consequently, two key intracellular pH regulators and
bicarbonate transporters are transcriptionally upregulated in the hq retina at four-months.
Solute carrier family 4, sodium bicarbonate transporter, member 10 (Slc4a10) is a
sodium-coupled bicarbonate transporter that exploits the transmembrane Na+ gradient in
neurons to uptake HCO3- and reduces acid load.172 Adenylate cyclase 10 (Adcy10) is
believed to be a universal, evolutionarily conserved bicarbonate sensor.173 Unlike other
intracellular pH regulators, Adcy10 functions as a bicarbonate sensor rather than a proton
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sensor which allows a more direct regulation of bicarbonate to maintain pH
homeostasis.174 Almost every cellular protein is sensitive to fluctuations in pH, however
ADCY10 exhibits a unique ability to remain functional during extreme pH
fluctuations.173 In addition, ADCY10 exhibits the ability to regulate the TCA cycle.
Discrepancy between generation and utilization of reducing agents (NADH and FADH2)
produced mainly by the TCA cycle, leads to ROS production and becomes harmful for
the cell.174 Adcy10 uses CO2 produced by the TCA cycle to serve as a metabolic signal for
TCA cycle turnover and can reduce the intra-mitochondrial cAMP concentration leading
to reduced output of the TCA cycle.174 Adcy10 is upregulated in both the four-month hq
retina and the four-month hq cerebellum inferring an increased cellular need for pH
homeostasis and TCA cycle regulation. High NADH/NAD+ ratios will also push
increased lactate production which has been observed in Aif-deficient cells and tissues of
the hq mouse.95,98,118 Expression analysis of Lactate dehydrogenase C (Ldhc), which
catalyzes the reverse reaction of lactate to pyruvate, was not examined due to low
transcript levels of the gene (Figure 4.2A
Previous transcriptome studies of the hq-mouse retina performed by our laboratory
are consistent with ammonia toxicity and protein degradation leading to amino acid
metabolism as a source for ATP generation in vivo.175 The catabolism of amino acids is
associated with the production of aldehyde by-products which can lead to glycation of
amino-acids,176,177 and subsequent inflammatory responses. Thereby, Aldehyde
dehydrogenase 2 (Aldh2) is likely transcriptionally upregulated in the hq retina to
eliminate toxic aldehydes as a consequence of increased amino acid catabolism.178
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4.12 The limitations of transcriptome analyses and future in vivo examinations
The transcriptome of the hq retina identifies many useful preliminary therapeutic
targets and potential early disease mechanisms, however many limitations exist with
transcriptome investigation. Transcriptional analysis occurs prior to post-transcriptional
processing, translation and post-translational regulation and therefore does not reflect the
quantity or functionality of the enzyme/protein in vivo. In addition, other interacting
targets may be responsible for the phenotype observed. Further examinations at the level
of the proteome are important for characterizing changes and complete interactions as a
result of the Aif downregulation in vivo. One recommendation is the examination of key
enzymatic factors of the glycerol pathway, GK5 and GPD2, to determine if increased
neuronal glycerol metabolism is a feasible mechanism for FADH2 production. In addition
to proteome analysis, gas-chromatography mass spectrophotometry could be used to
determine the in vivo concentrations of metabolites such as NADH, NAD+, lactate,
pyruvate, dihydroxyacetone phosphate, and FADH2 in comparison to the wild type. This
will give us better insight into the mechanisms that occur in the hq retina to cope with
NADH dehydrogenase dysfunction and reduced ATP production.

4.13 Preliminary suggestions for hq mitochondrial dysfunction therapy
In addition to transcriptome quantification, a preliminary study of metabolic rate
suggests that hq mice are hyperphagic and require increased food consumption. This is
likely the result of reduced OXPHOS function causing a reduced ratio of ATP produced
per molecule of glucose. hq mice are resistant to progressive weight gain and lipid
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accumulation when fed a high fat diet inferring potential reliance and utilization of
triglycerides as predicted.118 This is likely due to the fact that fatty acids and glycerol
yield a much higher FADH2 and NADH than glucose and are commonly used for
treatment of complex I deficiencies.162
From a therapeutic point of view, treatment of hq mice must take a direct approach
to correcting mitochondrial dysfunction. Increased glycerol metabolism in the hq mouse
predicts an increased reliance on FADH2 as the primary reducing agent in the
mitochondria. The benefits’ of a high fat diet are likely to reduce the severity of the hq
phenotype, although the benefits are unlikely to provide continued treatment due to
NADH accumulation in the cell. Thereby, a probable treatment may be in the form of
Riboflavin (vitamin B2). Riboflavin is a flavoprotein precursor and is the central
component of FAD. Treatment with riboflavin will allow the cell to produce more
FADH2 and facilitate the enzymatic reactions of the TCA cycle.179 Complex I and II
deficiencies show betterment of symptoms and delayed disease progression following
treatment with riboflavin.180–182

In addition, riboflavin has been used to treat human

patients with OXPHOS deficiency caused by an Aif amino-acid deletion (R201 del).183
Riboflavin treatment improves neurological symptoms and increases the functionality of
OXPHOS in these patients.183 Although the hq disease is associated with a severe
downregulation of Aif as opposed to a deletion of an amino acid, riboflavin
supplementation demonstrates a promising preliminary therapeutic treatment for
improving the hq disease.
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4.14 Conclusions
Retinal degeneration in the hq mouse is characterized by mitochondrial dysfunction
leading to parainflammation and closely mimics aging and mitochondrial-associated
retinal degeneration. Early disease mechanisms resulting in degeneration of the hq retina
are associated with early neurite losses and photoreceptor cell losses that can be
characterized by diagnostic oscillatory potentials. This study has developed a novel
framework for the analysis of the entire OP profile across multiple stimuli, allowing
functional examination of all retinal cell types and their health when combined with awave and b-wave analyse. We have identified diagnostic ERG markers associated with
the hq disease as well as a pipeline for identifying diagnostic ERG markers in other
models of retinal disease. Parainflammation in the hq retina is more likely the result of
endogenous retinal AIF deficiency and transcriptome alterations are consistent with
compensatory mechanisms of ATP production such as glycerol metabolism. Studies
aimed at a thorough characterization of glycerol metabolism as well as the accumulation
of specific primary metabolites will help elucidate the role of AIF and bring us closer to
understanding mitochondrial-associated retinal degeneration.
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This appendix contains figures and tables to assist with understanding of presented
material.
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Table B.1. PCR Primers used for Aif Genotyping
Primer Position

Sequence (5’ to 3’)

Amplicon
Length
(bp)

Forward

AGTGTCCAGTCAAAGTACCGGG

537 (WT)

Proviral Forward

GAACAAGGAAGTACAGAGAGAGGC

725 (hq)

Reverse

CTATGCCCTTCTCCATGTAGTT
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
925.19
925.12
925.22
925.31
925.26
925.36
925.33
925.45
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P

Adcy10
Gpd2
Aldh2
Gk5
Aifm1
Gapdh
Rn18s
Tbc1d4
Hk1
Glut4
Ldhc
Pdhx
Slc4a10
Adcy10 NTC

Gpd2 NTC

Aldh2 NTC

Gk5 NTC

Aifm1 NTC

Hk1 NTC

Glut4 NTC

Ldhc NTC

Pdhx NTC

Slc4a10 NTC

Gapdh NTC

Rn18s NTC Tbc1d4 NTC

Figure B.1. A representative diagram of Taqman® block design for 3 month mice.
The 384-well plate is divided into columns of three for each mouse and genes assayed are
represented by rows. A total of 13 genes were assayed per mouse in triplicate. A notemplate control (NTC) for each gene was assayed in rows O & P to ensure no false
amplification and was also assayed in triplicate.
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Table B.2. Pearson’s correlation coefficients from nonmetric multidimensional
scaling analysis of hqY time-domain OP parameters. Tables are ordered by
ascending Coordinate 1 value (left chart) and ascending Coordinate 2 value (right
chart) to assist with axis interpretation.
Measurement Coordinate 1 Coordinate 2
F11 Latency OP2
F11 Latency OP3
F9 Latency OP3
F10 Latency OP2
F8 Latency OP3
F10 Latency OP3
F9 Latency OP2
F9 Latency OP4
F8 Latency OP4
F8 Latency OP2
F9 Latency OP5
F10 Latency OP5
F10 Latency OP4
F11 Latency OP4
F11 Latency OP5
F8 Latency OP5
F11 Amplitude OP2
F10 Amplitude OP5
F10 Amplitude OP2
F9 Amplitude OP2
F11 Amplitude OP5
F8 Amplitude OP3
F8 Amplitude OP2
F9 Amplitude OP5
F8 Amplitude OP5
F8 Amplitude OP4
F9 Amplitude OP4
F9 Amplitude OP3
F10 Amplitude OP4
F11 Amplitude OP4
F10 Amplitude OP3
F11 Amplitude OP3

-0.859006334
-0.853657492
-0.846274465
-0.841057093
-0.830526046
-0.822981718
-0.82194351
-0.80694756
-0.799695375
-0.742677191
-0.733660057
-0.685039837
-0.684617696
-0.638909514
-0.468400077
-0.344040045
0.424307269
0.481785605
0.543878698
0.560034669
0.578306152
0.599566532
0.618144453
0.65045626
0.672790759
0.684464179
0.728464308
0.729042222
0.748886709
0.799065572
0.812086192
0.870065089

-0.151377761
-0.15753476
-0.169707181
-0.193566945
-0.065715862
-0.208552355
-0.125478715
-0.298008836
-0.207521146
-0.101943569
-0.250762361
-0.356267863
-0.529856532
-0.589130854
-0.541219708
-0.265368694
-0.412374408
0.164778075
-0.644420042
-0.66660931
0.186810407
-0.557316795
-0.461141832
-0.111703757
-0.40557432
-0.552811113
-0.343319214
-0.615488338
0.043278448
0.162761807
-0.448484634
-0.178484534

Measurement Coordinate 1 Coordinate 2
F9 Amplitude OP2
F10 Amplitude OP2
F9 Amplitude OP3
F11 Latency OP4
F8 Amplitude OP3
F8 Amplitude OP4
F11 Latency OP5
F10 Latency OP4
F8 Amplitude OP2
F10 Amplitude OP3
F11 Amplitude OP2
F8 Amplitude OP5
F10 Latency OP5
F9 Amplitude OP4
F9 Latency OP4
F8 Latency OP5
F9 Latency OP5
F10 Latency OP3
F8 Latency OP4
F10 Latency OP2
F11 Amplitude OP3
F9 Latency OP3
F11 Latency OP3
F11 Latency OP2
F9 Latency OP2
F9 Amplitude OP5
F8 Latency OP2
F8 Latency OP3
F10 Amplitude OP4
F11 Amplitude OP4
F10 Amplitude OP5
F11 Amplitude OP5

0.560034669
0.543878698
0.729042222
-0.638909514
0.599566532
0.684464179
-0.468400077
-0.684617696
0.618144453
0.812086192
0.424307269
0.672790759
-0.685039837
0.728464308
-0.80694756
-0.344040045
-0.733660057
-0.822981718
-0.799695375
-0.841057093
0.870065089
-0.846274465
-0.853657492
-0.859006334
-0.82194351
0.65045626
-0.742677191
-0.830526046
0.748886709
0.799065572
0.481785605
0.578306152

-0.66660931
-0.644420042
-0.615488338
-0.589130854
-0.557316795
-0.552811113
-0.541219708
-0.529856532
-0.461141832
-0.448484634
-0.412374408
-0.40557432
-0.356267863
-0.343319214
-0.298008836
-0.265368694
-0.250762361
-0.208552355
-0.207521146
-0.193566945
-0.178484534
-0.169707181
-0.15753476
-0.151377761
-0.125478715
-0.111703757
-0.101943569
-0.065715862
0.043278448
0.162761807
0.164778075
0.186810407
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Table B.3. Pearson’s correlation coefficients from nonmetric multidimensional
scaling analysis of hqY frequency-domain OP parameters. Tables are ordered by
ascending Coordinate 1 value (left chart) and ascending Coordinate 2 value (right
chart) to assist with axis interpretation.
Measurement
F10 Total Energy
F11 Total Energy
F9 Total Energy
F11 Gaussian Power
F10 Gaussian
Frequency
F8 Total Energy
F9 Gaussian
Frequency
F8 Gaussian
Frequency
F11
Gaussian
Frequency
F10 Gaussian Power
F9 Gaussian Power
F8 Gaussian Power

Coordinate 1 Coordinate 2

Measurement

-0.97963505
-0.968656764
-0.938426703
-0.837221842

-0.080079919
0.088457664
-0.236289954
-0.260841987

-0.821513771
-0.817230902

0.543230455
-0.292346888

-0.810590977

0.546777937

F9 Gaussian Power
F8 Gaussian Power
F10 Gaussian Power
F8 Total Energy
F11 Gaussian Power
F9 Total Energy
F10 Total Energy
F11 Total Energy
F10 Gaussian
Frequency

0.563671382
0.594753436
-0.563367817
-0.770721391
-0.745030923

F9 Gaussian
Frequency
F8 Gaussian
Frequency
F11 Gaussian
Frequency

-0.784149192
-0.776138181
-0.735730899
-0.590242553
-0.439755859

Coordinate 1 Coordinate 2
-0.590242553
-0.439755859
-0.735730899
-0.817230902
-0.837221842
-0.938426703
-0.97963505
-0.968656764

-0.770721391
-0.745030923
-0.563367817
-0.292346888
-0.260841987
-0.236289954
-0.080079919
0.088457664

-0.821513771

0.543230455

-0.810590977

0.546777937

-0.784149192

0.563671382

-0.776138181

0.594753436
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Table B.4. Pearson’s correlation coefficients from nonmetric multidimensional
scaling analysis of hqX frequency-domain OP parameters. Tables are ordered by
ascending Coordinate 1 value (left chart) and ascending Coordinate 2 value (right
chart) to assist with axis interpretation.
Measurement
F10 Latency OP2
F9 Latency OP2
F10 Latency OP3
F11 Latency OP3
F9 Latency OP4
F10 Latency OP5
F8 Latency OP2
F8 Amplitude OP3
F11 Latency OP2
F8 Amplitude OP4
F9 Latency OP5
F10 Latency OP4
F11 Latency OP4
F9 Latency OP3
F8 Amplitude OP5
F11 Latency OP5
F10 Amplitude OP5
F11 Amplitude OP5
F9 Amplitude OP5
F9 Amplitude OP4
F10 Amplitude OP4
F8 Amplitude OP4
F11 Amplitude OP4
F8 Amplitude OP5
F9 Amplitude OP3
F8 Amplitude OP3
F10 Amplitude OP3
F8 Amplitude OP2
F9 Amplitude OP2
F10 Amplitude OP2
F11 Amplitude OP3
F11 Amplitude OP2

Coordinate 1 Coordinate 2
-0.8465227
-0.84122833
-0.8286985
-0.7839018
-0.78382521
-0.77789174
-0.75190675
-0.74317829
-0.73761625
-0.73351111
-0.72513157
-0.67806932
-0.63576058
-0.61737348
-0.59553985
-0.27739875
0.12469163
0.1437659
0.33357947
0.37176222
0.3800024
0.42295653
0.48735872
0.50542379
0.59040284
0.61054609
0.64286454
0.65078245
0.68950648
0.76133209
0.76840952
0.78171173

-0.33263146
-0.26833499
-0.28526331
-0.39646655
-0.21714434
-0.07591251
-0.47672993
-0.22739861
-0.47558814
-0.04430713
-0.46055913
-0.06781597
-0.55236009
-0.35646637
-0.2987983
-0.23479761
-0.71649367
-0.68752732
-0.71742454
-0.87729291
-0.8572363
-0.74131346
-0.64154307
-0.54592269
-0.36471528
-0.72685793
-0.50677443
-0.34984908
-0.52237812
-0.36759832
-0.57446596
-0.41812742

Measurement
F9 Amplitude OP4
F10 Amplitude OP4
F8 Amplitude OP4
F8 Amplitude OP3
F9 Amplitude OP5
F10 Amplitude OP5
F11 Amplitude OP5
F11 Amplitude OP4
F11 Amplitude OP3
F11 Latency OP4
F8 Amplitude OP5
F9 Amplitude OP2
F10 Amplitude OP3
F8 Latency OP2
F11 Latency OP2
F9 Latency OP5
F11 Amplitude OP2
F11 Latency OP3
F10 Amplitude OP2
F9 Amplitude OP3
F9 Latency OP3
F8 Amplitude OP2
F10 Latency OP2
F8 Amplitude OP5
F10 Latency OP3
F9 Latency OP2
F11 Latency OP5
F8 Amplitude OP3
F9 Latency OP4
F10 Latency OP5
F10 Latency OP4
F8 Amplitude OP4

Coordinate 1 Coordinate 2
0.37176222
0.3800024
0.42295653
0.61054609
0.33357947
0.12469163
0.1437659
0.48735872
0.76840952
-0.63576058
0.50542379
0.68950648
0.64286454
-0.75190675
-0.73761625
-0.72513157
0.78171173
-0.7839018
0.76133209
0.59040284
-0.61737348
0.65078245
-0.8465227
-0.59553985
-0.8286985
-0.84122833
-0.27739875
-0.74317829
-0.78382521
-0.77789174
-0.67806932
-0.73351111

-0.87729291
-0.8572363
-0.74131346
-0.72685793
-0.71742454
-0.71649367
-0.68752732
-0.64154307
-0.57446596
-0.55236009
-0.54592269
-0.52237812
-0.50677443
-0.47672993
-0.47558814
-0.46055913
-0.41812742
-0.39646655
-0.36759832
-0.36471528
-0.35646637
-0.34984908
-0.33263146
-0.2987983
-0.28526331
-0.26833499
-0.23479761
-0.22739861
-0.21714434
-0.07591251
-0.06781597
-0.04430713
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Table B.5. Pearson’s correlation coefficients from nonmetric multidimensional
scaling analysis of hqX frequency-domain OP parameters. Tables are ordered by
ascending Coordinate 1 value (left chart) and ascending Coordinate 2 value (right
chart) to assist with axis interpretation.
Measurement
F9 Total Energy
F10 Total Energy
F11 Gaussian Power
F10 Gaussian Power
F8 Total Energy
F11 Total Energy
F9 Gaussian Power
F8 Gaussian Power
F8 Gaussian
Frequency
F9 Gaussian
Frequency
F10 Gaussian
Frequency
F11 Gaussian
Frequency

Coordinate 1 Coordinate 2
-0.969372022
-0.96440625
-0.947405504
-0.936559689
-0.925313065
-0.898996534
-0.852374157
-0.778672152

0.053267539
0.209308386
0.019228962
-0.249515924
0.134905804
0.364182853
-0.462860557
-0.477976579

-0.103790027

0.939471085

-0.088637167

0.951935284

-0.062301485

0.980003901

-0.045683178

0.969829489

Measurement
F8 Gaussian Power
F9 Gaussian Power
F10 Gaussian Power
F11 Gaussian Power
F9 Total Energy
F8 Total Energy
F10 Total Energy
F11 Total Energy
F8 Gaussian
Frequency
F9 Gaussian
Frequency
F11 Gaussian
Frequency
F10 Gaussian
Frequency

Coordinate 1 Coordinate 2
-0.778672152
-0.852374157
-0.936559689
-0.947405504
-0.969372022
-0.925313065
-0.96440625
-0.898996534

-0.477976579
-0.462860557
-0.249515924
0.019228962
0.053267539
0.134905804
0.209308386
0.364182853

-0.103790027

0.939471085

-0.088637167

0.951935284

-0.045683178

0.969829489

-0.062301485

0.980003901
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Figure B.2. A schematic representation of OP parameters elicited by a three month
hqY and wild-type mouse (10 cd•s/m2 stimulus). (A) Time-domain representation of
ERG OP parameters indicate functional changes as early as three months of age with
changes in OP periodicity. (B) Frequency-domain representation of ERG OP parameters
at three months indicate functional changes in OP frequency. It is evident that power, and
total energy are decreased in this schematic representation.
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Figure B.3. A schematic representation of OP parameters elicited by an eleven
month hqX and wild-type mouse (10 cd•s/m2 stimulus). (A) Time-domain
representation of ERG OP parameters indicate functional changes at eleven months of
age with changes in OP amplitude. (B) Frequency-domain representation of ERG OP
parameters at eleven months indicate functional changes in OP total energy and power. It
is evident that OP frequency remains unchanged in this schematic representation.
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Table B.6. Two-way ANOVA’s performed in Excel [Microsoft, Redmond, VA] on
oscillatory potentials parameters both in the time and frequency domain to explore
the effect of age on genotype. Significance is equal to p < 0.05.

A.

B.

C.

D.

hqY Time-Domain Parameters
Initial Latency

Summed Amplitude

Genotype (p < 0.001)

Genotype (p < 0.001)

Age (p = 0.07337)

Age = (p < 0.001)

Interaction (p = 0.212)

Interaction (p < 0.01)

hqY Frequency-Domain Parameters
Peak Frequency

Peak Power

Total Energy

Genotype (p < 0.001)

Genotype (p < 0.05)

Genotype (p < 0.01)

Age (p < 0.001)

Age (p < 0.01)

Age (p < 0.01)

Interaction (p < 0.05)

Interaction (p < 0.01)

Interaction (p < 0.01)

hqX Time-Domain Parameters
Initial Latency

Summed Amplitude

Genotype (p < 0.01)

Genotype (p < 0.001)

Age (p < 0.001)

Age (p = 0.63994 )

Interaction (p = 0.212)

Interaction (p = 0.15089)

hqX Frequency-Domain Parameters
Peak Frequency
Genotype (p < 0.01)
Age (p < 0.001)
Interaction (p = 0.88369)

Peak Power
Genotype (p < 0.001)
Age (p < 0.01)
Interaction (p = 0.16913)

Total Energy
Genotype (p < 0.001)
Age (p = 0.7796)
Interaction (p = 0.13802)
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Table B.7. Concentrations and quality assurance measures for extracted retinal and
cerebellar RNA samples.
Retina

4 Month

3 Month

2 Month

Concentration
Sample ID
A260/A280
(ng/µL)
*924.3
33.9
2.06
*925.16
41.7
2.04
*925.77
44.9
2.03
hq
*925.83
72.2
2.21
925.89
n/a
n/a
925.90
24
2.1
*925.93
72.3
2.13
924.4
n/a
n/a
*924.5
16.3
2.43
*924.11
23.7
2.01
*925.14
34.1
2.02
WT
925.72
n/a
n/a
*925.73
29.1
2.18
925.75
12.1
2.59
*925.95
41.1
2.11
*925.19
32.7
2.15
*925.22
16.2
1.85
hq
*925.26
32
2.04
925.27
35.6
2.05
*925.33
33.6
2.02
*925.12
43.9
2.05
925.13
12.8
2.23
WT *925.31
53.4
2.03
*925.36
29.6
2.1
*925.45
47.1
2.18
*925.53
26.6
2.12
925.54
8.2
2.21
hq
*925.55
52.9
2.11
*925.69
27
2.13
*925.70
50.2
2.1
*925.39
44.4
2.1
*925.43
31
2.18
WT *925.51
32.3
2.03
*925.58
36.1
2.15
925.57
17
2.36

Cerebellum
RIN
9.6
9.6
9.5
8.9
n/a
9.1
9.2
n/a
8.9
9.3
9.2
n/a
8.8
8.4
9.1
8.8
8.2
9.6
9
9.8
8.9
None
9.8
9.4
9.9
9.5
9.2
9.6
9.2
9.6
9.8
9.6
9.4
9.1
8.6

Concentration
Sample ID
A260/A280
(ng/µL)
*924.3
257.2
2.028
*925.16
185.6
2.053
*925.77
232
2.064
925.83
287.6
2.043
*925.89
231.2
2.141
925.90
n/a
n/a
925.93
n/a
n/a
*924.4
273.2
1.957
924.5
n/a
n/a
924.11
n/a
n/a
*925.14
140
1.977
925.72
146
2.086
*925.73
140
2.077
*925.75
210
2.315
925.95
n/a
n/a
*925.19
212
2.008
*925.22
210
2.05
925.26
216
2.050
*925.27
240
2.040
*925.33
154
1.873
*925.12
353.6
2.007
925.13
240
1.911
*925.31
84
1.812
*925.36
214
2.030
*925.45
85
2.095
*925.53
215
2.011
*925.54
182
1.97
925.55
199.6
1.965
*925.69
221.6
1.965
*925.70
167.2
2.133
925.39
110
2.202
*925.43
310
2.102
*925.51
194
2.008
*925.58
188
1.983
*925.57
209.2
2.135

RIN
9.3
9.2
8.8
8.7
8.8
n/a
n/a
9.3
n/a
n/a
8.8
9.1
8.9
9.2
n/a
8
9.1
7.5
8.2
9.1
7.7
7.6
8.8
8.3
9.2
8.8
8.8
9.3
8.9
9.1
8.9
8.5
9
8.6
9

*Indicates sample that was chosen for transcriptome analysis. In addition, light shadings
indicate that the sample was not used.
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Appendix C. MATLAB functions and Scripts
This appendix contains MATLAB scripts for the isolation of oscillatory potentials from
the original ERG waveform and fast Fourier transformation.
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MATLAB Script A. “P3fit” function written into MATLAB for modelling
photoreceptor contribution to the ERG.
function err = p3fit(rktd)
global datatofit timestofit
options.MaxFunEvals=1000000;
i = find(timestofit<rktd(3));
model(i) = 0;
j = find(timestofit>=rktd(3));
model(j)

=

rktd(1)*(1-exp(-rktd(2)*(timestofit(j)-

rktd(3)).*(timestofit(j)-rktd(3))));
err = sum((model' - datatofit).^2);
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MATLAB Script B. “P3driver” function written into MATLAB for modelling
photoreceptor contribution to the ERG, followed by a fifth order Butterworth
transformation (65-300Hz) for oscillatory potential waveform extraction.

global datatofit timestofit
options.MaxFunEvals=1000000;
for icol = 16:19
clear model
%modelling the p3
%details
minval = min(data(:,icol));
imin = find(data(:,icol) == minval);
iremain = data(imin+1:200,icol);
timestofit = data(1:imin,1);
datatofit = data(1:imin,icol);
datatofit = datatofit - datatofit(1);
initialguess = [ min(datatofit) 0.5 0];
rktd = fminsearch(@p3fit,initialguess);
i = find(timestofit<rktd(3));
model(i) = 0;
j = find(timestofit>=rktd(3));
model(j)

=

rktd(1)*(1-exp(-rktd(2)*(timestofit(j)-

rktd(3)).*(timestofit(j)-rktd(3))));
k = (find(iremain)+(imin));
model(k) = min(model);
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timestoplot(i) = i;
timestoplot(j) = j;
timestoplot(k) = k;
%Subtracting model from data to form p2
p2(i) = ((data(i,icol)-data(1,icol)) - model(i)');
p2(j) = ((data(j,icol)-data(1,icol)) - model(j)');
p2(k) = ((data(k,icol)-data(1,icol)) - model(k)');
%Butterworth filtering the p2
Wn = [65 300] / 500;
[B,A] = butter(5,Wn);
fildata = filter(B,A,p2);
%Plots to see how things are going
figure
subplot(2,1,1),hold on,
plot(data(:,1),data(:,icol)-data(1,icol));
plot(timestoplot,model,'r');
plot(timestoplot,p2,'g');
plot(timestoplot,fildata,'black');
subplot(2,1,2),plot(timestoplot,fildata,'black');
end
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MATLAB Script C. “P3driverFFT” function written into MATLAB for modelling
photoreceptor contribution to the ERG, followed by a fifth order Butterworth
transformation (65-300Hz) and fast Fourier transformation (Gaussian).
global datatofit timestofit
options.MaxFunEvals=1000000;
for icol = 16;
clear model
%modelling the p3
%details
minval = min(data(:,icol));
imin = find(data(:,icol) == minval);
iremain = data(imin+1:200,icol);
timestofit = data(1:imin,1);
datatofit = data(1:imin,icol);
datatofit = datatofit - datatofit(1);
initialguess = [ min(datatofit) 0.5 0];
rktd = fminsearch(@p3fit,initialguess);
i = find(timestofit<rktd(3));
model(i) = 0;
j = find(timestofit>=rktd(3));
model(j)
=
rktd(1)*(1-exp(-rktd(2)*(timestofit(j)rktd(3)).*(timestofit(j)-rktd(3))));
k = (find(iremain)+(imin));
model(k) = min(model);
timestoplot(i) = i;
timestoplot(j) = j;
timestoplot(k) = k;
%Subtracting model from data to form p2
p2(i) = ((data(i,icol)-data(1,icol)) - model(i)');
p2(j) = ((data(j,icol)-data(1,icol)) - model(j)');
p2(k) = ((data(k,icol)-data(1,icol)) - model(k)');
%Butterworth filtering the p2
Wn = [65 300] / 500;
[B,A] = butter(5,Wn);
fildata = filter(B,A,p2);
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fs = 1000;
t = 0:1/fs:0.2-1/fs;
x = (fildata);
b
m
n
y
f
p

=
=
=
=
=
=

% Sample frequency (Hz)
% 10 sec sample

fildata(1:128);
% Window length
length(b);
pow2(nextpow2(m)); % Transform length
fft(x,n);
% DFT
(0:n-1)*(fs/n);
% Frequency range
sqrt(y.*conj(y)/n);
% Power of the DFT

plot(f(1:floor(n/2)),p(1:floor(n/2)))
xlabel('Frequency (Hz)')
ylabel('Power')
title('{\bf Periodogram}')
A=((p(1)/2 +sum (p(2:end-1) + p(end)/2))/2) % area under
the curve
%Plots to see how things are going
%figure
%subplot(2,1,1),hold on,
%plot(data(:,1),data(:,icol)-data(1,icol));
%lot(timestoplot,model,'r');
%plot(timestoplot,p2,'g');
%plot(timestoplot,fildata,'black');
%subplot(2,1,2),plot(timestoplot,fildata,'black');
g = fit(f.',p.','gauss2')
plot(g)
end
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Appendix D. Non-metric multidimensional scaling R code.
This appendix contains R code for performing non-metric multidimensional scaling
on oscillatory potential parameters in both the time and frequency domain.
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NMDS R-code A. Non-metric multidimensional scaling performed by calculating
Euclidean distances between samples followed by subsequent correlation analysis.

> getwd()
# This will list the location that R will read files from
> list.files()
#List of all files in the working directory
> data <- read.csv(“ZSCORES HQY&XY FFT DATA.csv”)
# Information in file will become a variable named “data”
> data
# View “data” variable
> (D <- dist(data))
# This will calculate Euclidean distance between each
sample
based
on
input
z-scores.
Presented
as
a
#dissimilarity matrix, assigned as variable D.
> summary (D)
# Displays dissimilarity matrix
> library (“MASS”)
# Reads in library package to perform NMDS
# Install the HSAUR2 package
> data_mds <- isoMDS(D)
# This will perform NMDS on the dissimilarity matrix (D)
based on 50 iterations. Assigns NMDS as #data_mds
> x <- data_mds$Points[,1]
# Assigns the first coordinate of the NMDS variables to the
variable x
> y <- data_mds$Points [,2]
# Assigns the first coordinate of the NMDS variables to the
variable y
# Variables plotted in excel
# NMDS coordinates put into a new z-score file and read
into excel for correlation analysis
> x <- read.csv("ZSCORES
(ERIC DOLINAR).csv")

(Coorelation)

HQY&XY

FFT

DATA
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# Assigns variable x to z-score file with NMDS coordinates
> cor(x, use = "complete.obs", method = "pearson")
# Performs a Pearson’s correlation on the variable x
# Shepard plots
> MDS.sh <- Shepard (D, data_mds$points)
> plot(MDS.sh, pch =".")
> plot(MDS.sh, pch =".", xlab = "Dissimilarity", ylab =
"Distance")
> lines(MDS.sh$x, MDS.sh$yf, type="S")
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Appendix E. Functional annotation of differentially expressed retinal genes
This appendix contains functional annotations based on NCBI Gene searches184 of
521 retinal genes differentially expressed in hq mice at four months of age. Differential
expression is based on a retinal gene expression microarray [Affymetrix, Mouse Gene 1.0
ST Array, Santa Clara] previously performed by the Hill laboratory.102
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Table E.1. Functional annotation of 521 differentially expressed retinal genes based
on microarray data from four-month-old hq disease mice.*
Gene Symbol

p-value‡

Fold
Change

Annotation/Function†

Aifm1

0.000163

-6.01196

Cyp3a25

0.0307866

-4.68949

Hc

0.0116071

-3.90775

Ttc18

0.0024609

-3.43071

Trim36

0.0275573

-3.41135

Abca6

0.0450953

-3.09029

Iqgap2

0.0440039

-3.01678

Myh6

0.0058866

-2.90362

Slc4a10

0.0266117

-2.87259

Robo3

0.0008035

-2.81071

Mitochondrial intermembrane flavoprotein involved in
OXPHOS and apoptosis
Cytochrome P450 variant involved in metal binding and
oxidoreductase activity
Complement activation (C5) and innate immune
response
Extracellular vesicular exosome important to ciliated
cells
Ubiquitin ligase activity with zinc-binding protein
activity
ATP-binding cassette involved in macrophage lipid
metabolism and homeostasis
Regulates cell morphology and mobility through
interaction with the cytoskeleton
Encodes heavy chain of myosin, an intracellular motor
protein
Neuronal intracellular bicarbonate transporter and pH
regulator
Controls neurite outgrowth and axonal navigation

Olfm4

0.015151

-2.77354

Antiapoptotic protein and facilitates cell adhesion

Haus6

0.0362302

-2.70602

Microtubule and kinetochore assembly

Atm

0.0358792

-2.69275

Cell cycle checkpoint kinase protein

Nbr1

0.0227154

-2.64043

Peroxisome autophagic degradation

BC030307

0.0060405

-2.62532

Unknown

Slc26a4

0.0160909

-2.60606

Sulfate and chloride transporter

Dpy19l1

0.0274067

-2.54374

Unknown

Ppp1r9a

0.0149737

-2.53199

Phosphatase I involved in cytoskeleton organization

4930519F16Rik

0.0061143

-2.51977

Unknown

Wdr60

0.0071325

-2.51121

Cell cycle regulator and formation of cilia

D19Ertd652e

0.0298091

-2.50222

Unknown

Pdhx

0.0161061

-2.48204

Aqp4

0.0018312

-2.47148

Structural component of pyruvate dehydrogenase, binds
subunits together
Neuronal aquaporin to allow water-selective transport

Pkd1l2

0.0066857

-2.46823

Cation channel pore, cation transport

Siglece

0.0321588

-2.46084

BC055324

0.0449079

-2.40619

Garnl1

0.0495052

-2.38863

Smc1b

0.0466303

-2.3795

Klra5

0.0094125

-2.36588

Pear1

0.0419941

-2.35637

Sialic acid binding protein involved in immune cell
response
Unknown
Activation of Ral GTPase
Mitotic and meiotic DNA recombination and chromatid
formation
Membrane protein involved in cellular adhesion during
immune response
Responsible for platelet aggregation
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Trio

0.0159855

-2.345

Adal

0.0032844

-2.3368

Promotes leukocyte transendotheial migration
Purine, drug and small molecule catabolism

Kmo

0.0428267

-2.32506

4922505G16Rik

0.0380333

-2.30153

Mitochondrial protein involved in NADH oxidase
activity and FAD binding
Unknown

Mansc1

0.03965

-2.28514

Plasma membrane component

Rbms3

0.0109571

-2.27729

Cytoplasmic RNA metabolism

Golga3

0.0392264

-2.27699

Car1

0.0257676

-2.2678

Hdc

0.0008771

-2.23775

Ankfy1

0.0015828

-2.23773

Conversion of L-histidine to histamine involved in
neurotransmission
Cytoplasmic protein and vesicle transport

Msh3

0.0048097

-2.2069

Initiates post-replication DNA mismatch repair

Dnahc2

0.0235939

-2.20618

Involved in axonemal microtubule formation

Apaf1

0.0367202

-2.19996

Col7a1

0.0174913

-2.19387

Sall2

0.0137244

-2.18272

Golgi apparatus transport of proteins and lipids to
nucleus during mitosis
Catalyzes to reversible hydration of carbon dioxide

Cytoplasmic initiator of apoptosis through formation of
apoptosome
Component of collagen and extracellular remodelling

Katnal2

0.0307008

-2.1754

Involved in transcriptional regulation during growth and
development of neurons
Microtubule severing through ATPase activity

Slc38a11

0.0438682

-2.17502

Plasma membrane amino acid and sodium transporter

Col4a2

0.02681

-2.16956

Npy2r

0.0213178

-2.16915

Rad50

0.0452278

-2.16269

Nmbr

0.039171

-2.15422

Tada3l

0.0106471

-2.15409

Component of collagen involved in inhibiting
angiogenesis
Neuropeptide signalling activity
DNA double-stranded break repair and cell cycle
regulation
Binds neuromedin B to promote mitosis
Promotes DNA-binding of transcriptional factors
NF-kappa B signalling to regulated inflammation and
immune response
Involved in mRNA translation initiation

Nlrp3

0.0341535

-2.15371

Dhx29

0.0398495

-2.15276

Col9a2

0.0063438

-2.14271

Abca16

0.0127381

-2.13578

Component of collagen involved in extracellular
remodelling and axon guidance
ATP-binding cassette, function unknown

Duox2

0.0052049

-2.11419

NADH oxidase activity and cytokine release

Wrn

0.0050367

-2.1116

RNA and DNA helicase

Pard3b

0.0249889

-2.10666

Involved in cell cycle and tight junction formation

Ptpru

0.0008582

-2.10598

Clasp2

0.048169

-2.08765

Grin2b

0.0422529

-2.0848

Dnahc11

0.0020171

-2.06752

Glutamate receptor for prominent neurotransmitter in the
retina
Ciliary dynein protein from microtubule motor activity

4921528I07Rik

0.0376126

-2.06285

Unknown

Ms4a4c

0.0019349

-2.06017

Unknown

Protein binding regulation of cell growth, differentiation
and mitosis
Microtubule end binding and anchoring
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Thyroglobin (thyroid hormone)

Tg

0.0232324

-2.06013

Nudt13

0.0313719

-2.05882

Unknown
Integral membrane protein - tyrosine transport

Oca2

0.0226697

-2.05639

Itgal

0.013379

-2.05613

Scn5a

0.0192309

-2.04663

Spna1

0.0108579

-2.04024

Integrin expressed in leukocytes for intracellular
adhesions
Sodium channel, voltage-gated
Actin cytoskeleton organization

Dpp10

0.0499214

-2.03872

Coq7

0.0001781

-2.03198

Serine protease and binds K+ channels and alters
functionality
Coenzyme Q involved in ubiquinone biosynthesis

Rfc1

0.0063545

-2.02704

DNA replication factor C for DNA replication

Telo2

0.008154

-2.00621

S-phase checkpoint protein

Nlrc5

0.0164919

-2.0028

Inhibits NF-kappa-B activation and interferon signalling

Brca1

0.021531

-2.00024

Casc5

0.0081067

-1.99927

L3mbtl

0.0497075

-1.99779

Tumour suppressor acts as a DNA damage sensor and
mediates repairs
Microtubule-kinetochore attachments and chromosome
separation
Chromatin modification and cell cycle regulation

2310033E01Rik

0.0307551

-1.98669

Phospholipidase inhibitor

Lctl

0.00774

-1.96934

Glycosidase

Tcp10b

0.0271985

-1.96595

Unknown
Mediates mitochondrial fusion

Mfn1

0.0067646

-1.96589

Pfkfb3

0.0191326

-1.96108

2610034M16Rik

0.0169822

-1.96036

Activator of the glycolysis pathway through early
primary steps
Unknown

Lars2

0.0062127

-1.95613

Aminoacyl-tRNA synthetase

Aox4

0.0361653

-1.94431

Cdh23

0.0006493

-1.94368

Ptbp2

0.0088319

-1.94299

Neuronal RNA regulatory protein

Aldehyde oxidase involved in biosynthesis of retinoic
acid
Intracellular adhesion glycoprotein

Pla2g4d

0.0325627

-1.94056

Phospholipidase, liberates fatty acids

Wdr52

0.0464484

-1.93782

mRNA processing and/or cytoskeleton assembly

Csmd1

0.0052928

-1.93496

Integral membrane protein

Txndc3

0.0474444

-1.93491

Unknown
Unknown, potential for CNS development

BC059842

0.0456172

-1.93344

Scnn1b

0.0456916

-1.93172

C1qtnf5

0.001318

-1.92401

Sodium channel, voltage-gated control of electrolytes
across epithelia
Basement membrane and cell adhesion

Ift140

0.0364322

-1.91511

Microtubule formation of cilia

Cdx4

0.0260372

-1.9096

RNA polymerase core promoter binding protein

Hephl1

0.006727

-1.90675

Copper ion transport

Slc5a4a

0.0281977

-1.90241

Unknown, transporter protein

9030420J04Rik

0.0062036

-1.90156

Unknown

Nphp4

0.0382606

-1.89934

Microtubule development and function
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Hkdc1

0.0242806

-1.8967

Kinesin-like microtubule motor protein, mitotic
chromosome segregation
Hexokinase activity and glucose metabolism

Nbeal2

0.0373284

-1.89554

Regulates neurotransmitter receptor trafficking

Pole

0.019369

-1.89426

DNA polymerase subunit

Gucy2c

0.0005898

-1.89361

Enterotoxin receptor

Acot12

0.0272659

-1.89312

Acetyl-CoA hydrolase activity

Lhx8

0.0443032

-1.89031

DNA binding transcription factor

1700040L02Rik

0.0025767

-1.88678

Kif2c

0.0299502

-1.89863

Abcc5

0.0410045

-1.88581

Cep152

0.0360524

-1.88357

Gm6190

0.0055903

-1.87934

Unknown, important for cilia function
ATP-binding cassette involved in export of cyclic
nucleotides
Microtubule centrosome function
Unknown

Lrp2

0.0249245

-1.8778

Stag3

0.0005808

-1.87163

Uptake of lipoproteins, sterols, hormones and vitamins
from extracellular space
Cohesion of sister chromatids during mitosis

4930555F03Rik

0.0406336

-1.8666

Unknown

Prkdc

0.0292855

-1.86298

Vps13c

0.0425298

-1.85981

Optc

0.0157026

-1.85973

Col27a1

0.0486116

-1.85899

Binds collagen fibrils and regulations fibril formation
and morphology
Component of structural extracellular matrix

Enoph1

0.0344511

-1.85735

Unknown, amino-acid metabolism

Cd2ap

0.0110717

-1.85617

Mcm5

0.0444294

-1.85324

Usp33

0.0228026

-1.85306

Deubiquinating enzyme

Protein kinase mediates double-stranded break DNA
repair
Unknown

Scaffolding protein involved in organization of actin
cytoskeleton
Facilitates cell cycle and mitosis initiation

Lcp2

0.0018684

-1.85165

T-cell receptor and immune response

Senp6

0.0247478

-1.85165

Ubiquitin-like molecule

Hsd17b3

0.0295071

-1.84551

Conversion of androstenedione to testosterone

2010204N08Rik

0.0058221

-1.84151

High carbohydrates induces histone acetylation

Setdb1

0.0326697

-1.83627

Mediates gene silencing and transcriptional repression

Lef1

0.0049875

-1.8353

Transcription factor for T-cell receptors

Kndc1

0.0267347

-1.8341

Gm6986

0.0120064

-1.82782

Col6a2

0.020632

-1.8273

Ippk

0.0300244

-1.82475

Timeless

0.0430905

-1.82091

C730048C13Rik

0.0126639

-1.82063

Component of collagen binds extracellular matrix
proteins
Mediates DNA repair and endocytosis through inositolphosphate signalling
Involved in DNA polymerase activity, telomere
maintenance and cell morphology
Unknown, solute carrier

Slc9a10

0.0313326

-1.82026

Na+ transporting carboxylic acid decarboxylase

Enah

0.011655

-1.81313

Axon guidance and T-cell receptor signalling

Regulates Ras GTPase activity and dendrite
morphogenesis
Unknown

157
Zfp597

0.0215991

-1.81127

Unknown

Mbd2

0.0030594

-1.81122

Binds methylated DNA and represses transcription

4430402I18Rik

0.0030179

-1.80948

Unknown

B3galtl

0.0208824

-1.80685

Beta 1,3-galactosyltransferase

Vps13b

0.0355605

-1.80646

Intracellular vesicle protein transport of CNS

Lgr5

0.0418022

-1.8045

G-protein-coupled receptor
DNA helicase for DNA repair

Chd1l

0.039933

-1.80225

Rnf10

0.0066076

-1.80152

Hmcn1

0.0369989

-1.79986

Wdr90

0.0235019

-1.79898

Ccdc33

0.032919

-1.79699

Unknown

Ring finger protein DNA binding and transcription
regulation
Immunoglobin, involved in anchorage of neurons to
epidermis
Unknown

Pcsk5

0.0191332

-1.79594

Protein trafficking through the endoplasmic reticulum

Htr3b

0.049761

-1.79425

Ion channel for fast, depolarizing response in neurons

Myh7b

0.000595

-1.79347

Heavy chain of myosin (transport)

F11

0.0400904

-1.79324

Factor 11 in blood coagulation

Col4a3

0.0341158

-1.79188

Component of collagen

Zbtb17

0.0187941

-1.78929

Regulation of c-myc (transcription factor)

Srrt

0.031086

-1.78731

Regulation of transcription

Chkb

0.0003588

-1.78714

Tecrl

0.0019138

-1.7857

Alg13

0.0429268

-1.78543

Lipid oligosaccharide biosynthesis

Formation of phosohocholine or phosphoethanolamine
by kinase activity
Unknown

Ank3

0.0474462

-1.78453

Ankyrin, cytoskeleton anchoring and cell mobility

Hnf1a

0.0046702

-1.78376

Liver transcription factor

Clic6

0.0270728

-1.78355

Chloride channel, intracellular transport

Myo7a

0.01778

-1.78178

Myosin component, compromised in retinal degeneration

Ubr2

0.0197904

-1.78082

Ubiquitin protein ligase, targets proteins for degradation

Clcn1

0.0254486

-1.77847

Chloride channel, voltage-sensitive (muscle)

Cdkl4

0.0059487

-1.777

Cyclin dependent kinase, cell cycle regulation

Hdac7

0.0285512

-1.77682

Eme2

0.0158106

-1.77538

Histone deacetylase, transcription and cell cycle
regulation
Endonuclease involved in DNA repair

Myh15

0.0186594

-1.77466

Myosin component, motor activity

Myo15

0.0261537

-1.77444

Myosin component, motor activity

Lypd6b

0.0207377

-1.77414

Unknown

Reg3d

0.0443465

-1.77411

Enhances glucose tolerance, unknown function

Vti1a

0.0191915

-1.76861

Vesicle transporting, SNARE interactions

Tyr

0.035644

-1.76852

Facilitates conversion of tyrosine to melanin

Morc1

0.0141049

-1.76743

Potential in regulating apoptosis

Ciz1

0.0417301

-1.76299

Zinc-finger protein for CDKN1A interaction

Itgb2l

0.0265953

-1.76047

Integrin, intracellular adhesions

C8a

0.0459502

-1.76019

C8 of complement system
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Cenpk

0.0417527

-1.75707

Kinetochore assembly and mitosis progression

Ahctf1

0.0486254

-1.75615

Transcription factor for mitotic gene transcription

Ltbp2

0.0023953

-1.75599

Growth factor, involved in cell adhesion

Dnahc12

0.0032213

-1.75459

Dynein, microtubule motor activity

Chd4

0.0391803

1.75029

DNA helicase, histone modifications

Plg

0.0028306

1.75042

Inhibitor of angiogenesis

Fras1

0.0203383

1.75069

Extracellular matrix protein for cell adhesion

Rbl2

0.0395343

1.75129

Retinoblasma-like involved in cell cycle regulation

Steap3

0.0263896

1.75146

Ferrireductase

Ldlr

0.0340576

1.75369

Ostf1

0.0028003

1.75443

Low density lipoprotein receptor, endocytosis,
cholesterol metabolism
Cell adhesion, unknown function

Nusap1

0.0061925

1.75444

Nucleus spindle microtubule formation and integrity

Esyt1

0.0333224

1.75465

Unknown

Cdh19

0.0447529

1.75584

Cadherin, glycoprotein involved in cell adhesion

Ptpn14

0.0377965

1.75649

Mitosis, microtubule associated

Plbd2

0.0444493

1.75824

Phospholipase B, lipid metabolism

Trim37

0.0419797

1.75946

Protein-protein interactions

Mov10l1

0.0119256

1.76008

RNA helicase (testis)

Asap3

0.0050632

1.76035

Promotes differentiation, cell morphology and mobility

Plcb2

0.0048519

1.76224

Phospholipase C, lipid metabolism, synaptic function

Rictor

0.0231411

1.76235

Component of MTOR, growth factor

Arfgap3

0.0098453

1.76245

GTPase activity, promotes vesicle transport

Col5a3

0.0262117

1.76265

Component of collagen

Scn11a

0.0163679

1.76309

Sodium channel, voltage gated, ion regulation

Lbp

0.0303646

1.76368

Immune response, binds lipopolysaccharides

Aire

0.0118822

1.76399

Binds CREB, regulates expression of immunity genes

Dkc1

0.0101854

1.76501

DNA damage repair

Hepacam2

0.0296601

1.76551

Promotes mitosis and metaphase

Mmp14

0.0165032

1.76592

Extracellular matrix remodelling

Nln

0.02361

1.76613

Formation of neurotensin

Plcb3

0.0120545

1.76731

Phospholipase C, lipid metabolism, signal transduction

Ubash3b

0.0103796

1.7674

Ubiquitin domain inhibits endocytosis of growth factor

Psat1

0.0206356

1.77061

Skap2

0.0081311

1.771

Phosphoserine aminotransferase involved in
schizophrenia
Responsible for src signalling pathway

Strc

0.0479517

1.77119

Stereocilin involved in stereocilia formation

Atf5

0.0004549

1.77199

Transcription factor inhibiting astrocyte differentiation

Fam83b

0.0452632

1.77223

MAPK activation and epithelial cell transformation

Vwf

0.0212629

1.77274

Glycoprotein involved in blood coagulation

Irak3

0.0261513

1.77409

Cchcr1

0.0388618

1.77477

Interleukin receptor, inhibits Toll-like receptors in glial
cells
Cellular organization and proliferation

Pls3

0.0403178

1.77554

Plastin involved in actin-binding
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Ifih1

0.0230229

1.77892

Patz1

0.0384599

1.77933

Siae

0.0263821

1.78277

RNA helicase to remove secondary structure, ribosomal
formation
DNA binding transcription factor and chromatin
remodelling
Deacetylation of sialic acids

Qk

0.0243801

1.78342

RNA binding protein for oligodendrocyte differentiation

Ctnna3

0.0031298

1.7871

Intercellular interactions, cell adhesion

Plin3

0.0392788

1.78726

Col3a1

0.0050813

1.78733

Mannose receptor for transport of lysosomal hydrolase
to endosome
Component of collagen

Dock9

0.0227907

1.78862

Mediator of cytokinesis

Cdkn1a

0.0200694

1.7907

Cell checkpoint cell, mediates DNA damage repair

Cd53

0.0165928

1.7919

Fam129b

0.0432193

1.79195

Cell growth and mobility, recruits T cells and
macrophages
Junction protein, can inhibit apoptosis processes in vivo

Mtmr12

0.0174133

1.79408

Lipid phosphatase

Trpv5

0.0410751

1.79854

Calcium channel involved in ion regulation
Heterochromatin protein to maintain chromatin structure

Cbx1

0.0095426

1.80234

Unc93b1

0.0204658

1.80241

Clic4

0.038684

1.80258

Regulates Toll-receptors trafficking from endoplasmic
reticulum, immune response
Chloride channel, intracellular pH and transport

Nsun2

0.0348147

1.80296

mRNA translation, ensures codon/anti-codon matching

Trpm5

0.0190737

1.80627

Cation channel, ion homeostasis

Tmem2

0.0164632

1.80853

Extracellular organization

Dpyd

0.017076

1.80883

Slc4a4

0.0342031

1.80922

Uracil and thymidine metabolism, rate-limiting
pyrimidine metabolism
Bicarbonate transported for intracellular pH maintenance

Slc25a30

0.0216791

1.81068

Small molecule inner mitochondrial matrix transporter

Spef2

0.011715

1.81131

Unknown

Slamf7

0.0089023

1.81231

Inhibits production of inflammatory cytokines

Rap1gap

0.0231372

1.81419

GTPase activity

Atp5g1

0.0464895

1.81564

E030010N08Rik

0.0221112

1.81575

Mitochondrial ATP synthase for proton transport during
OXPHOS
Unknown

Rbl1

0.0417279

1.81876

Retinoblasma-like involved in cell cycle regulation

Brip1

0.0323628

1.81949

Gbp10

0.0079526

1.82162

Interacts with BRAC1 to mediate double-stranded DNA
break repair
Immune response via interferon activation

Erbb2

0.0414782

1.82236

Epidermal growth factor involved in mitosis activation

Ano5

0.0304613

1.82246

Anoctamin calcuium-cholride channel

Atp13a5

0.025178

1.82328

ATPase, unknown function

Ifltd1

0.0465649

1.8238

Unknown

Depdc1b

0.0204587

1.82578

GTPase activation

Rnf213

0.0016575

1.82609

Zinc-finger protein for inter-protein interaction

Lrp2bp

0.0483587

1.82778

Unknown
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Actin binding, unknown function

Klhl4

0.037315

1.82864

Dapk2

0.0441918

1.82947

Regulator of pre-programmed cell death

Ddx60

0.0002651

1.83023

RNA helicase to remove secondary structure

Fyttd1

0.0002602

1.83227

Unknown

Lcp1

0.0305862

1.83464

B-cell and T-cell activation and cell migration

Sh3pxd2a

0.0016584

1.8374

Regulates invadopodia (extracellular protrusions)

Ccnb3

0.0017382

1.838

Cyclin involved in cell cycle regulation

Cfb

0.0018594

1.83836

Tmc3

0.0438492

1.84376

Complement factor B for complement activation and
leukocyte recruitment
Ion transport, unknown function

Nmt2

0.0001749

1.84398

N-myristoyltransferase 2

Naip5

0.0364918

1.84443

Plcg2

0.0092755

1.84448

Dock1

0.0133594

1.84479

Gbp5

0.0440096

1.84668

Apoptosis inhibitory protein, inhibits proteins involved
in apoptosis
Phospholipase C, signal transduction and cellular
messaging
Dedicator of cytokinesis, induces cell migration and
phagocytosis
Stimulates inflammation response to foreign antigens

Cyp27a1

0.0372999

1.84918

Cytochrome P450 variant, drug metabolism

Zfp330

0.0358616

1.85066

Zinc finger protein, unknown function

Ttc12

0.0098723

1.85072

Unknown

Wdr64

0.0307521

1.85187

Unknown

Cadps2

0.0171056

1.85342

Calcium secretion, synaptic function in neurons

Itga8

0.0114879

1.85524

Integrin, intracellular adhesions, cytoskeleton formation

Atp1a4

0.0212119

1.85636

Tmem77

0.007951

1.85869

ATPase, Na+/K+ transporter, neuron electrochemical
gradient maintenance
Cellular apoptosis inducing

Slc25a13

0.0030538

1.86195

Mitochondrial glutamate/aspartate transfer

Parp12

0.018547

1.86243

mRNA post-translational modifications, ADP ribose

Hydin

0.0313929

1.86592

Cilia formation

Oprm1

0.0181287

1.87057

Opioid receptor, neuronal G-protein

Rps6ka1

0.0374657

1.87268

Ribosomal protein kinase, controls cell differentiation

Gpr64

0.025621

1.87376

G protein-coupled receptor, transmembrane

Mthfd2

0.0019253

1.87397

Nuclear mitochondrial NAD sequestering

Nid2

0.0172362

1.87464

Binds collagen, involved in cell adhesion

Lsp1

0.0468358

1.8747

Ppfia4

0.0098483

1.87761

1700003E16Rik

0.0106796

1.88475

Immune cell expression, involved in cell adhesion and
extracellular remodelling
Protein tyrosine phosphatase, receptor type, tyrosine
phosphorylation
Unknown

Btk

0.0300985

1.88622

Formation and functionality of B-cells

Maged1

0.0174606

1.88731

Programmed cell death, cancer antigen presentation

Slc22a4

0.0382704

1.89398

Solute carrier, cations and zwitterion transport

Egfr

0.0279557

1.89959

Epidermal growth factor receptor, cell proliferation

Fanci

0.0060002

1.90404

Fanconi anemia, complementation group I activation
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Muc5b

0.0041903

1.90453

Sympk

0.0036757

1.90828

Meox1

0.019515

1.9114

Mucin 5B, glycosylated protein involved in mucus
formation
Post-transcriptional processing, involved in
polyadenylation
Developmental signalling

Atp2c2

0.0266884

1.91293

ATPase, cation transporter, neuron function

Ano1

0.0409161

1.91376

Padi2

0.0202878

1.91377

Apoe

0.0235635

1.9157

Anoctamin 1, calcium activated chloride channel,
epithelial repair
Post-translational modifications mediated by calcium,
CNS
Apolipoprotein E, metabolism of triglycerides (liver)

Ncf2

0.0177262

1.91758

Oxidoreductase activity, neutrophil specific

Map3k6

0.0247556

1.91763

Mitotic activated protein kinase

Dock11

0.0036392

1.91909

Dedicator of cytokinesis 11, extracellular remodelling

BC057079

0.0142697

1.92342

Focadhesin, cell adhesion, unknown function

Col6a3

0.0133423

1.92357

Component of collagen, extracellular matrix binding

Ppp1r12c

0.0066925

1.92469

Elmo3

0.0392572

1.92727

Protein phosphatase 1, cytoskeleton formation and
organization
Engulfment of apoptotic cells, inflammation

Ccdc88c

0.0496785

1.93007

Developmental interactions, wnt signalling

Abca8b

0.0061563

1.9319

ATP-binding cassette, unknown function

Dnahc17

0.0288871

1.93335

Dynein, microtubule motor activity

Lrrfip1

0.026914

1.9367

DNA, RNA binding, regulation of transcription

Slc7a7

0.0483406

1.94032

4833423E24Rik

0.0361036

1.94104

Solute carrier, amino acid transporter (cationic and
neutral)
Unknown

Sytl1

0.0258357

1.94714

GTPase activating protein

Rtkn

0.0205158

1.9493

Rhotekin scaffold protein inhibits GTPase Rho

Orc6l

0.0257836

1.95019

Initiates DNA replication in the nucleus

Sec24d

0.045669

1.95193

Vesicle transporting in vivo
Binds poly-A tail of mRNA, unknown function

Pnldc1

0.0114914

1.95203

Ppp2r1b

0.0226536

1.95427

Abca14

0.0374404

1.95828

Grhl3

0.0425524

1.96065

Sorbs2

0.0308871

1.96262

Hk1

0.0367158

1.96385

Itpr3

0.0090388

1.96463

Pyroxd2

0.0302111

1.96623

Hexokinase, glucose metabolism and glycolysis
regulation
Inositol 1,4,5-trisphosphate receptor, regulates calcium
homeostasis
Unknown

Soat1

0.0179412

1.96706

Formation of fatty acids and cholesterol

Eng

0.043215

1.97004

Vascular endothelial glycoprotein receptor

Slc7a1

0.0123391

1.97223

Solute carrier, cationic amino acids

Trim6

0.0210848

1.9726

Unknown

Protein phosphatase, regulates protein function in vivo,
cancer associated
ATP-binding cassette, unknown function
Developmental transcription factor, endothelial cell
migration
Cytoskeleton modifications
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Fbxl13

0.0324725

1.97696

Cleave ubiquitin from ubiquitination products

Spata6

0.0456238

1.9815

Spermatogenesis, cell differentiation, unknown function

Lrrc9

0.0356599

1.9848

Unknown

Myh3

0.0268801

1.98504

Myosin component, motor activity, cell transport

Zfp599

0.0370838

1.9856

Zinc finger protein, unknown function

2310008H04Rik

0.0400248

1.98643

Unknown

Cacna1h

0.0118042

1.98808

Tbc1d4

0.0315198

1.99166

Dhx40

0.0420537

1.99427

Calcium channel, voltage-dependent, maintenance of
membrane potentials
Mediates transport of GLUT4 from endoplasmic
reticulum to plasma membrane
RNA metabolism, helicase

Cep250

0.0243675

1.99597

Centrosome formation and function during mitosis

Gk5

0.0480136

1.99773

Primary, regulatory step of glycerol metabolism

Slc12a1

0.0416418

1.99777

Solute carrier, unknown function

Abca9

0.0438495

1.99907

ATP-binding cassette, unknown function

Klk1b16

0.0251047

2.00083

Unknown

Lama2

0.01227

2.0026

Atp8b1

0.0192593

2.00292

Baiap3

0.0003945

2.00342

Igfbp3

0.0358018

2.00685

Angiogenesis regulator in the brain, involved in synaptic
function
Insulin-like growth factor binding protein

Lmna

0.0164179

2.00747

Nuclear lamin, nucleus stability and chromatin structure

Ephx1

0.0429007

2.00765

Laminin component, extracellular component for
remodelling and organization
Aminophospholipid transporter

Scn4b

0.0418185

2.0079

Conversion of epoxides to trans-dihydrodoils for
excretion
Sodium channel, voltage-gated

Samd4

0.0318405

2.00926

RNA-binding, postranscriptional regulation

Cyfip1

0.0210452

2.0136

Regulates cytoskeleton and axon growth/formation

Fbln2

0.0057021

2.01365

Extracellular, neuronal structure development

Ankrd26

0.0291523

2.02058

Ankyrin, protein-protein interactions

Eya4

0.0268545

2.02241

Eye development, transcription activation

Mx2

0.0307161

2.02348

Ifnar2

0.0370614

2.02687

Dynamin and GTPase activity, heterochromatin
formation
Interferon receptor, activates Janus kinases

Wdr62

0.0108659

2.03409

Cerebral development, function unknown

Kif14

0.0261951

2.03591

Kinesin, microtubule motor protein for transport

Aldh1l1

0.0205617

2.03926

Syk

0.0130348

2.04443

Ddb2

0.0142656

2.04721

Aldehyde dehydrogenase for removal of cytotoxic
aldehydes
Tyrosine kinase involved in cell proliferation,
differentiation and phagocytosis
DNA damage repair from UV light damage

Flnc

0.0458499

2.04823

Filamin involved in anchoring of actin cytoskeleton

4930452B06Rik

0.0425945

2.05001

Unknown

Kntc1

0.0116476

2.05073

Mitotic chromosome separation during anaphase

Arhgef10

0.0173248

2.0533

Rho GTPase, stimulates G-proteins
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Lamc2

0.0297158

2.05539

Stab1

0.0215188

2.05942

Notch1

0.0027652

2.06196

Laminin component, extracellular component for
remodelling and organization
Stabilin, receptor that endocytoses AGES, bacteria and
lipoproteins
Intracellular signalling pathway mediator

BC006779

0.0150289

2.06524

DNA helicase, transcriptional activation

Klf4

0.0404938

2.06701

Transcription regulation and activation

Sfmbt2

0.0316905

2.07112

Regulation of transcription

Rgs22

0.0449781

2.0731

Regulator of G-protein signalling
Cation ATPase channel for phospholipid transport

Atp8b4

0.0050661

2.07605

Pde2a

0.0162072

2.07675

Col25a1

0.0282262

2.07705

Phosphodiesterase, regulates endothelial cell
proliferation and angiogenesis
Component of collagen, brain specific

Tmbim1

0.0386395

2.07758

Inhibits apoptosis by reducing FAS trafficking

Abcc3

0.0025065

2.07795

ATP-binding cassette, transport of anions

Msn

0.0492673

2.07988

Sult5a1

0.0181227

2.08116

Baiap2l1

0.0451011

2.08365

Col19a1

0.0015986

2.08366

Pnpla7

0.0413459

2.08459

Col5a2

0.0343231

2.08489

Moesin, links plasma membrane to actin as well as
filopodia formation
Unknown
Remodelling of the plasma membrane and cytoskeleton
pedestal formation
Component of collagen, maintenance of extracellular
matrix
Lipid metabolism, function unknown
Component of collagen

Tap2

0.0128675

2.08507

Fgfr2

0.0317797

2.08935

Fblim1

0.0248279

2.10192

ATP-binding cassette, transport of peptides to
endoplasmic reticulum
Fibroblast growth factor receptor, mitosis and
differentiation
Cell-cell adhesion modifications

Ecm2

0.0480193

2.10255

Extracellular matrix protein, function unknown

Dock2

0.0211604

2.10412

Cytoskeleton modifications for lymphocyte mobility

Taf1d

0.0085981

2.11135

RNA transcription regulation

Col1a2

0.0138499

2.11752

Component of collagen

Magt1

0.023233

2.12737

Magnesium transporter, N-glycosylation associated

Nckap1l

0.0115969

2.12884

Cell morphology regulation (hematopoietic)

Ccdc150

0.0115571

2.12925

Unknown

Cd68

0.0202543

2.13446

Svep1

0.0457553

2.13766

Glycoprotein in microglial cells, promotes activation of
macrophages
Unknown

Frem2

0.0232823

2.13927

Basement membrane epithelia protein

Vwa1

0.008256

2.14086

Extracellular matrix protein

Pebp4

0.0195098

2.14353

Lipid binding, unknown

Lrrk1

0.0116593

2.14701

Unknown

Gbp4

0.0277205

2.15078

Guanylate binding protein, interferon induced

Plcl2

0.009802

2.152

Phospholipase C, modifications to GABA receptors

Sgsm1

0.0143354

2.15698

G-protein signalling, GTPase activity

164
Cytokine CC, activates T-lymphocytes

Ccl24

0.0205018

2.15907

Kitl

0.0309238

2.16085

Kif20a

0.0312462

2.16108

Tyrosine-kinase receptor, neural cell development, cell
mobility
Kinesin, microtubule motor protein for transport

Dnahc1

0.0089948

2.17058

Dynein, microtubule motor activity

Calcrl

0.0195045

2.17483

Calctonin receptor

Abcc4

0.0495595

2.18036

ATP-binding cassette involved in anion cycling

Abca13

0.0068074

2.18061

ATP-binding cassette, transport (unknown function)

H2-D1

0.0232616

2.1838

Major histocompatibility component
Heparanase, component of extracellular matrix and cell
mobility
5'-nucleotidase protein

Hpse

0.0361428

2.18872

Nt5dc1

0.0014142

2.19853

Abca12

0.0210858

2.20527

ATP-binding cassette, small molecule transport

Ecm1

0.0133792

2.20762

Cell structure interaction for extracellular remodelling

Pth1r

0.0414317

2.21192

Parathyroid hormone receptor

Mertk

0.0157256

2.21711

Myom2

0.0104973

2.21919

MER/AXL/TYRO3 receptor kinase, involved in RPE
phagocytosis regulation
Myomesin 2, muscle cell component

Clca1

0.0381724

2.22377

Chloride channel accessory protein

Pappa2

0.0093243

2.22752

AW551984

0.0204154

2.23252

Regulates intracellular insulin-like growth factor
availability
Unknown

Nrap

0.0457788

2.23485

Nebulin-related anchoring protein, actin binding

Myo5c

0.0035317

2.23524

Myosin component, actin motor activity

Pld2

0.0463916

2.23549

Serpina3a

0.0458079

2.23824

Hydrolysis of phosphatidylcholine, cell cycle and
transcription regulation
Serine peptidase inhibitor

Iqgap3

0.0152522

2.23908

GTPase activation

Ermp1

0.026493

2.24009

Endoplasmic reticulum metallopeptidase

Tnxb

0.0431861

2.24326

Tenascin, reduces cell adhesion

Fut8

0.0406937

2.24542

Transfers fucose to glycopeptides

4933428G20Rik

0.0347269

2.24603

Unknown

Mpa2l

0.0362691

2.24733

Macrophage activation like, GTPase activity

Trpm4

0.0428844

2.25314

Calcium ion channel, non-selective

Myof

0.0059642

2.27105

Membrane vesicle formation, membrane fusion

Pkhd1l1

0.0083783

2.2745

Potential role in immune response

Poln

0.0388691

2.2817

DNA polymerase subunit

Fn1

0.0160342

2.2906

Fibronectin glycoprotein, cell mobility

Sfrp4

0.0167618

2.29162

Regulates Wnt signalling, receptor protein

Myh11

0.02687

2.30494

Myosin, microtubule motor activity

Plin1

0.0405267

2.30902

Lipid storage, lipolysis regulation and inhibition

Ccdc46

0.0344049

2.31067

Unknown

Efcab7

0.0026008

2.32595

Unknown

Scml2

0.033619

2.33493

Transcription regulation (inhibition), polycomb protein
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Myo15b

0.0067032

2.33608

Myosin, microtubule motor activity

Cd93

0.0376391

2.33913

Immune response to apoptotic cells, cellular migration

Aldh2

0.0450249

2.34462

Kynu

0.0160715

2.34696

C920025E04Rik

0.0365824

2.34911

Aldehyde dehydrogenase for removal of cytotoxic
aldehydes
Amino acid metabolism of tryptophan, NAD
regeneration
Major histocompatibility binding protein

Galnt3

0.0292916

2.35444

Polypeptide N-acetylgalactosaminyltransferase

Dse

0.0420728

2.36637

Induces immune response

Gpd2

0.0399365

2.37661

Secondary step of glycerol metabolism, glycerol shuttle

Pdzrn4

0.0249827

2.39325

Zinc-ring finger protein, unknown function

Adhfe1

0.0358737

2.39843

Alcohol dehydrogenase

Vipr1

0.0160948

2.40598

Activation of adenylate cyclase

Fxyd5

0.0435462

2.40968

B2m

0.0238666

2.42012

Renbp

0.0156324

2.42411

Ion transport regulator, functions during high chemokine
production
Major histocompatibility complex heavy chain
associated, microglial activation
N-acetylglucosamine metabolism

Dlec1

0.0277845

2.4261

Deleted in cancer progression, unknown function

Itpr2

0.039317

2.43982

Inositol 1,4,5-trisphosphate receptor, cell signalling

Slc44a5

0.0399251

2.44105

Solute carrier, unknown function

Igtp

0.0366583

2.44422

Interferon gamma subunit

Fas

0.0160064

2.45018

TNF receptor for cell apoptosis

Mvp

0.0233917

2.45571

Regulates MAP kinase for drug metabolism

Ncapd2

0.0265338

2.46031

Binds histones during mitosis

Sec16b

0.0451595

2.46535

Tspan12

0.0455787

2.47621

Endoplasmic reticulum organizational transport of
mature proteins
Cell surface tetraspanin for cell growth and mobility

Slc15a1

0.0488859

2.48534

Oligopeptide transporter for protein metabolism

Osmr

0.0118207

2.49015

Interleukin receptor for inflammation response

Gm7298

0.0104095

2.49301

Unknown

Thsd7b

0.0234948

2.51864

Unknown

1700011F14Rik

0.0159698

2.53491

Unknown

Clic5

0.0454731

2.54845

Chloride intracellular channel

Diap1

0.038375

2.54863

Axon guidance and elongation

Nup133

0.0421358

2.54899

Formation of nuclear envelope during mitosis

Mmel1

0.0193461

2.56265

Endopeptidase for phosphate homeostasis

Atp10d

0.0486888

2.57034

Obfc2a

0.0140833

2.57695

Nos2

0.0316639

2.58763

ATPase ion transport across concentration and
electrochemical gradients
Single-stranded DNA binding protein for replication,
repair and recombination
Nitric oxide synthase for regulation of nitric oxide

F3

0.0378579

2.58869

Factor 3 in blood coagulation

Dnahc8

0.0312568

2.60645

Dynein, microtubule motor activity

2.60932

Immunoglobin, synaptic maintenance

Sdk2

0.0422683
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Pola1

0.0082495

2.61239

Myo1e

0.0024885

2.61773

Subunit of DNA polymerase involved in initiation of
DNA replication
Non-muscle myosin for actin motor activity

Dysf

0.0130688

2.64452

Membrane repair and regeneration

Zfp748

0.0486775

2.67676

Unknown, zinc-finger protein

Csmd2

0.00496

2.68896

Unknown

Mllt4

0.0447334

2.70289

Cast

0.0018883

2.71118

Aox3l1

0.0153934

2.71173

Organization of cell junctions and extracellular
interactions
Calpain inhibitor which is involved in neuronal vesicle
trafficking
Retinol and amino-acid metabolism

Asah2

0.0132518

2.71609

Production of sphingosine, induce apoptosis

Fndc3c1

0.0074993

2.72731

Fibronectin

Lama3

0.0032464

2.78592

Extracellular remodelling and migration

Rassf2

0.0486192

2.78738

Tumor suppressor gene, Ras associated

Mug1

0.0151463

2.80096

Unknown

Cps1

0.0242031

2.81088

Il18r1

0.0389371

2.81156

Myh9

0.0255247

2.82263

B230120H23Rik

0.0352319

2.82642

Unknown

Primary, regulatory step of urea cycle and ammonia
removal
Interleukin receptor for microglial activation and
cytokine release
Non-muscle myosin for cell mobility and morphology

Utp20

0.0292205

2.84246

Small nucleolar RNA for 18S assembly

Abca15

0.0133014

2.84975

ATP-binding cassette

Adcy10

0.0050507

2.85833

Intracellular bicarbonate sensor and pH regulator

Dock10

0.0090131

2.89996

Directs cytokinesis

Hhip

0.0086926

2.91551

Involved in hedgehog recruitment for development

Nrk

0.0136839

2.94234

Activates JNK pathway

Clspn

0.0035071

2.94334

Cell cycle checkpoint protein, arrests cell cycle

Gmnn

0.0215492

2.99088

Inhibits DNA replication, cell cycle checkpoint protein

Cd97

0.0149192

2.99546

Xdh

0.0064959

3.00028

Intercellular interactions, involved in leukocyte
activation and recruitment
Metabolism of purines, involved in microglial activation

Myo1c

0.0374662

3.00731

Myosin component for actin motor transport

Als2cl

0.0282106

3.0433

Protein localization and transport

Myo1f

0.0001664

3.04358

Myosin component for microtubule transport

H2-K1

0.0371741

3.06774

Major histocompatibility component

Nfkbil2

0.0214434

3.14832

Inhibits NF-kappa-B activation

F13a1

0.0234937

3.21301

Factor 13 in blood coagulation

Plec1

0.0253006

3.22776

Unknown

Kif4

0.0073226

3.3724

Kinesin microtubule motor activity

Trpm6

0.0435942

3.47521

Ion channel for magnesium transport in epithelial cells

Csmd3

0.0211546

3.53038

Unknown

Bub1b

0.0050054

3.78249

Spindle checkpoint to inhibit cell cycle until proper
chromosome separation
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Dpp4

0.0179589

4.02866

Muc5ac

0.0183852

4.03264

T-cell activation, involved in immune response
Extracellular remodelling
103

* Microarray was performed by A. Laliberté (2010).

Cut-offs set at: Fold change > ±

1.75, p < 0.05.
†

Annotation based on NCBI Gene184 [National Center for Biotechnology Information,

U.S. National Library of Medicine, Bethesda MD]
‡ Pathway is ordered by increasing p-value.
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